Co-expression of natriuretic peptide receptors and its implications on receptor regulation in smooth muscle cells of the aorta by Waisbrod, Guy
  
 
Co-expression of natriuretic peptide receptors and its implications 
on receptor regulation in smooth muscle cells of the aorta 
 
 
 
 
Inaugural Dissertation 
submitted to the 
Faculty of Medicine 
In partial fulfillments of the requirements 
for the Doctor medincinae Degree 
of the Faculty of Medicine 
of the Justus-Liebig University Giessen 
 
 
 
by 
Guy Waisbrod 
of 
Tiberias, Israel 
 
Giessen 2011 
 
  
From the Institut für Anatomie und Zellbiologie 
Chairman: Prof. Dr. Wolfgang Kummer 
of the Faculty of Medicine of the Justus-Liebig University Giessen 
 
 
 
 
 
 
 
 
 
 
 
 
First Supervisor: Prof. Dr. Ralf Middendorff 
Second Supervisor: Prof. Dr. Heinrich Sauer 
 
Date of Doctoral Defense: 20. 03. 2012 
 
 
 
 
Table of Contents 
 
1 Introduction           7 
1.1  Natriuretic peptides          7 
1.1.1   Biosynthesis and structure of natriuretic peptides     8 
1.2  The Natriuretic Peptide Receptors       8 
1.2.1  Structure of guanylyl cyclase-linked natriuretic peptide receptors 11 
1.2.1.1   Extracellular domain      13 
1.2.1.2   Transmembrane domain     13 
1.2.1.3   Kinase homology domain     13 
1.2.1.4   Hinge region       14 
1.2.1.5   Guanylyl cyclase catalytic domain    14 
1.3 Activation and Regulation of Guanylyl Cyclase-linked receptors 14 
1.3.1  Activation of GC-A and GC-B     14 
1.3.2  Regulation of GC-A and GC-B     15 
1.3.2.1   Receptor phosphorylation     15 
1.3.3  Homologous desensitization      16 
1.3.4  Heterologous desensitization     17 
1.4 Signaling Pathways        19 
1.4.1  cGMP-dependent protein kinase (PKG)    19 
1.4.2  cGMP-regulated phosphodiesterases (PDEs)   21 
1.4.3  Cyclic nucleotide-gated ion channels (CNG)   21 
1.5 Aims of the Study        22 
1.5.1  Background        22 
1.5.2  Experiments with rat aorta                 23
   
 
 
2 Materials and Methods        26 
2.1 Materials         26 
2.1.1   Wistar rats        26 
2.1.2  Reagents, solutions and substances    26 
2.2 Methods         29 
2.2.1  Vessel preparation       29 
2.2.2  Immunohistochemistry (IHC)      30 
2.2.3  Protein extraction       31 
2.2.4  Western blot        32 
2.2.4.1   SDS- Polyacrylamide gel electrophoresis (SDS-PAGE) 32 
2.2.4.2   Protein transfer to membranes (Blotting)   33 
2.2.4.3   Immunostaining of membranes    34 
2.2.5  Affinity cross-linking       35 
2.2.6  Isometric tension studies      35 
2.2.7  Measurement of cGMP production     38 
2.2.7.1  Enzyme-linked immuno-sorbent assay (ELISA)   39 
2.2.8  Data presentation and statistical analysis    40 
 
3 Results          41 
3.1 Characterization of natriuretic peptide receptors in vasculature 41 
3.1.1 Immunohistochemical analysis of GC-A and  
GC-B expression in rat aorta      41 
3.1.2 Immunoblot analysis of GC-A and GC-B expression in rat aorta 44 
3.1.3 Affinity labeling of natriuretic peptide receptors, 
GC-A, GC-B and NPR-C in rat aorta    45 
3.2        Isometric tension studies with rat aorta     47 
3.2.1 Vasorelaxant potency of ANP     48 
3.2.2 Vasorelaxant potency of CNP     49 
3.2.3 Vasorelaxant potency of the NPR-C ligand cANF   51 
3.2.4 ANP-induced relaxation      52 
3.2.5 ANP-induced relaxation after pretreatment with 100 nM CNP 52 
3.2.6 ANP-induced relaxation after pretreatment with 50 nM CNP 
 54 
3.2.7 ANP-induced relaxation after pretreatment  
with PKA-inhibitor and 50 nM CNP     57 
3.3       Measurement of cGMP production in rat aorta    59 
3.3.1   ANP is more potent than CNP to stimulate  
cGMP production in rat aorta     60 
3.3.2 Pre-treatment with CNP enhances  
ANP-induced cGMP production     61 
3.3.3 Pre-treatment with different CNP concentrations   63 
3.3.4 GC-A sensitization is mediated through PKA   64 
3.3.5 CNP-induced GC-A sensitization is mediated  
through activation of GC-B      65 
3.3.6 Homologous desensitization of GC-A    67 
3.3.7 Homologous desensitization of GC-A is mediated through PKG 68 
3.3.8 CNP-elicited sensitization of GC-A  
under conditions of PKG inhibition     70
     
 
4 Discussion         72 
4.1     Physiological roles of GC-A and GC-B in mammals   72 
4.2     Mechanisms of receptor regulation     74 
4.3     Co-expression of GC-A and GC-B in rat aorta    77 
4.4     CNP/GC-B signaling sensitizes GC-A     79 
4.5     Sensitization of GC-A is mediated via PKA    81 
4.6     The aorta: a crucial independent target organ  
for natriuretic peptides?       85 
 
 Summary          87 
Abbreviations         90 
References          93 
Declaration          105 
Acknowledgement        106 
 
Introduction 
___________________________________________________________________ 
7
1 Introduction 
1.1 Natriuretic Peptides 
A long predicted humoral link between the heart and the kidney was found by de 
Bold, by isolating a substance from atrial cardiac tissue capable of eliciting a rapid 
decrease of blood pressure, accompanied by increased diurese (de Bold, Borenstein 
et al. 1981). Soon, two related peptides, possessing a common disulfide linked ring 
structure, were purified.  
The family of these natriuretic peptides consists of atrial natriuretic peptide (ANP), 
brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP). Structurally 
related but genetically distinct, these hormones (ANP, BNP) or paracrine factors 
(CNP) regulate blood pressure and blood volume and play a crucial role in 
modulating ventricular hypertrophy, fat metabolism, bone growth and pulmonary 
hypertension among others (Maack, Suzuki et al. 1987; Stein and Levin 1998; Kuhn 
2004; Potter, Abbey-Hosch et al. 2006). Both ANP and BNP are synthesized in atrial 
cardiomyocytes and secreted into circulation in response to cardiac wall stretch. 
Thus they exert important cardiovascular functions by acting as true endocrinal 
factors (Brenner, Ballermann et al. 1990; Ruskoaho 1992). By contrast, the third 
member, CNP, is mainly produced in vascular endothelial cells and chondrocytes 
while also found in high concentrations in brain tissue. It exhibits various local and 
paracrine functions in the cardiovascular system as well as outside of it (Sudoh, 
Minamino et al. 1990; Suga, Nakao et al. 1992; Hagiwara, Sakaguchi et al. 1994).  
For the sake of completeness another peptide of this family, urodilantin, should be 
mentioned. This peptide represents an elongated form of ANP, produced exclusively 
in the kidney (Schulz-Knappe, Forssmann et al. 1988). 
Evolutionary analyses uncovered CNP as the most ancient family member of 
natriuretic peptides, suggesting that both ANP and BNP evolved from CNP gene 
duplications (Inoue, Naruse et al. 2003). 
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1.1.1 Biosynthesis and structure of natriuretic peptides 
 
All members of the natriuretic peptides family are synthesized as so called 
preprohormones. The length of human preproANP is 151 amino acids and cleavage 
of the N-terminal signal sequence results in a precursor protein, proANP, of 126 
amino acids. This molecule is the predominant form to be stored in granules. Upon 
secretion, biologically active ANP emerges after a second cleavage, catalyzed by a 
protease called corin, as a 28-amino acid carboxyl-terminal fragment (Yan, Wu et al. 
2000).  
The signal sequence of human preproBNP is cleaved likewise to form a proBNP 
containing 108 amino acids. Further proteolytical process leads to a mature 32-amino 
acid BNP. The protease responsible for this process is not identified yet. 
Mature CNP is known to exist in two variants, a 22- and a 53-amino acid form, each 
derived from the 103-amino acids proCNP. While the enzyme responsible for the 53-
amino acid version is identified as forin, the protease for processing the 22-amino 
acid CNP is unknown. Although similar if not identical in function, tissue expression 
of both CNP forms differs (Potter, Abbey-Hosch et al. 2006): CNP-22 is found mainly 
in human plasma and  cerebral spinal fluid, CNP-53 predominates in brain tissue, 
vascular endothelial cells and the heart (Minamino, Makino et al. 1991; Stingo, 
Clavell et al. 1992; Togashi, Kameya et al. 1992; Totsune, Takahashi et al. 1994).   
The three mature natriuretic peptides contain a common 17-residue disulfide-linked 
ring structure (Yandle 1994; Levin, Gardner et al. 1998; Stein and Levin 1998). This 
ring along with parts of the N- and C-terminal extensions are essential for the 
natriuretic peptides to exert their biological activity (Chen and Burnett 1998).  
 
1.2 Natriuretic Peptide Receptors 
 
There are three known transmembrane receptors binding natriuretic peptides: NPR-
A, NPR-B and NPR-C, “NPR” standing for natriuretic peptide receptor. They are also 
referred to as guanylyl cyclase A (GC-A), guanylyl cyclase B (GC-B) and the 
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clearance receptor, stressing the fact that GC-A and GC-B are guanylyl cyclases 
(Potter 2005), while the latter lacks any guanylyl cyclase activity and is involved in 
metabolic clearance of the peptides (Fuller, Porter et al. 1988). Hence, GC-A and 
GC-B convert guanosine triphosphate into cyclic 3’,5’-guanosine monophosphate 
(cGMP). Thus, cGMP is the second messenger in the signaling pathways of 
natriuretic peptides (Lucas, Pitari et al. 2000). The cGMP-generating receptors 
resemble growth factor receptor topology, containing an extracellular ligand-binding 
site (approximately 450 amino acids), a single hydrophobic membrane-spanning 
domain and an intracellular region of about 570 amino acids (Potter 2005).  
GC-A mRNA is expressed in many tissues and cell types. It is predominantly found in 
kidney, adrenal, vascular, pituitary and fat tissue (table 1). GC-B is observed in 
above mentioned tissues, though in a more restricted manner. Additional expression 
sites such as chondrocytes are reported (Lucas, Pitari et al. 2000; Potter, Abbey-
Hosch et al. 2006). The clearance receptor was localized to atrial, kidney and venous 
tissue as well as to smooth muscle cells and endothelial cells of the aorta (Fuller, 
Porter et al. 1988; Porter, Arfsten et al. 1990; Nagase, Katafuchi et al. 1997).  
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Table 1: Natriuretic peptide receptors, their ligand preferences, sites of expression and 
physiological functions 
NATRIURETIC PEPTIDE 
RECEPTOR 
LIGAND 
PREFERENCES 
SITES OF 
EXPRESSION 
MAIN FUNCTIONS 
GC-A (NPR-A) ANP>BNP>>CNP Kidney, vasculature, 
heart, brain, lung, 
pituitary, testis, smooth 
muscle cells (additional 
sites are reported) 
Vasorelaxation, 
natriuresis, diuresis, 
inhibition of renin and 
aldosterone secretion, 
regulation of cell 
proliferation 
 
GC-B (NPR-B) CNP>>ANP>BNP Kidney, vasculature, 
heart, brain, lung, 
pituitary, pineal gland, 
penis, endothelium, 
ovary, uterus, 
chondrocytes 
(additional sites are 
reported) 
Vasorelaxation, 
regulation of bone 
growth, control of 
neuronal differentiation, 
regulation of hormone 
secretion 
Clearance receptor 
(NPR-C) 
ANP, BNP, CNP Kidney, vasculature, 
testis, lung, placenta, 
mesentery (additional 
sites are reported) 
Regulation of local 
concentrations of 
natriuretic peptides, 
inhibition of adenylyl 
cyclase 
 
 
The three members of the natriuretic peptide family bind differentially to these 
receptors. 
The rank order binding affinity for GC-A is ANP greater than BNP and much greater 
than CNP. The affinity rank order for GC-B is almost completely inversed, with CNP 
as the most potent activator and BNP with the least potency (Koller, Lowe et al. 
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1991; Suga, Nakao et al. 1992; Lopez, Garbers et al. 1997). These findings suggest 
that GC-A is the main binding protein for ANP and BNP, whereas GC-B represents 
the endogenous receptor for CNP. In contrast the clearance receptor, binds all three 
receptors with similar affinity (Bennett, Bennett et al. 1991; Suga, Nakao et al. 1992; 
Kuhn 2004; Potter, Abbey-Hosch et al. 2006). The physiological role of this third 
natriuretic peptide receptor is not fully understood. It has been shown that the 
clearance receptor keeps natriuretic peptides from circulation via internalization, thus 
modulating their circulating and local concentrations (Maack, Almeida et al. 1988; 
Jaubert, Jaubert et al. 1999; Matsukawa, Grzesik et al. 1999; van den Akker 2001). 
Furthermore, some reports postulate that NPR-C reduces adenylyl cyclase activity in 
membranes or decrease cAMP concentrations in whole cells (Anand-Srivastava, 
Sairam et al. 1990). The clearance receptor has also been shown to stimulate 
phospholipase C (Berl, Mansour et al. 1991; Murthy, Teng et al. 2000; Pagano and 
Anand-Srivastava 2001). In addition it should be mentioned, that unlike GC-A and 
GC-B, the clearance receptor binds the synthetic ANP analog called cANF. Functions 
stimulated by this substance, lacking the carboxyl-terminal tail and a part of the 
disulfide ring structure, can be attributed to NPR-C (Maack, Suzuki et al. 1987; 
Potter, Abbey-Hosch et al. 2006). 
 
1.2.1 Structure of guanylyl cyclase-linked natriuretic peptide receptors 
Basically, membrane guanylyl cyclases share a common topology containing an 
extracellular ligand binding domain at the N-terminus, a short hydrophobic 
transmembrane part and an intracellular site with the catalytic component at its C-
terminal end. Hence, the basic structures of GC-A and GC-B are quite similar. As 
described above, their extracellular domain consists of approximately 450 amino 
acids whereas the single hydrophobic transmembrane region is about 20-25 
residues. The intracellular domain consists of three further subdivisions: a 
juxtamembranous protein kinase-homology domain, an amphipathic hinge region of 
41 amino acids as well as a roughly 250-amino acid C-terminal cyclase-homology 
catalytic domain (Potter and Hunter 2001; Kuhn 2003). In the absence of their ligand, 
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GC-A and GC-B exist as homodimers. The hinge region mediates the oligomerization 
of the receptors (Forte and Currie 1995).  Deletion of this region has proved to result 
in monomeric inactive entities. Therefore dimerization is essential for the activation of 
the catalytic domain (Kuhn 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Common structure of the cGMP-generating natriuretic peptide receptors 
The basic topology of GC-A and GC-B consists of a ligand binding extracellular domain, a single 
hydrophobic transmembrane domain and an intracellular domain. The latter can be further subdivided 
into a kinase homolgy domain and a catalytic domain, bisected by a hinge region. As the figure 
indicates, the receptors exist as homodimers (Kuhn 2003).  
 
 
 
 
 
 
 
Extracellular domain 
Transmembrane domain 
Kinase homology domain (KHD) 
Hinge region 
Cyclase homlogy domain (CHD) 
GTP cGMP 
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1.2.1.1 Extracellular domain 
The extracellular region of the receptors represents the site of binding the natriuretic 
peptide. Though similar in topology, the difference in primary structure provide the 
specifity for ligand binding, thus it is the most dissimilar region between the two 
proteins (Potthast and Potter 2005). The mechanism of ligand binding is not 
completely resolved and studies are discordant about ligand-receptor stoichiometry, 
ranging between 1:1 (Shyjan, de Sauvage et al. 1992; Lowe, Dizhoor et al. 1995), 2:2 
(Schulz, Lopez et al. 1997; Yang, Robinson et al. 1999) and 1:2 (Fulle, Vassar et al. 
1995). Latter is underpinned by novel reports that propose an A-shaped head-to-
head dimerization with a stoichiometry of one molecule of ligand to two molecules of 
receptor (Ogawa, Qiu et al. 2004; Potter, Abbey-Hosch et al. 2006).  
 
1.2.1.2 Transmembrane domain 
The single transmembrane span represents the part which divides the receptor 
molecule into an extracellular and an intracellular domain while its hydrophobic 
configuration allows it to be integrated in the hydrophobic cell membrane. Besides its 
localization further functions are still unraveled. 
 
1.2.1.3 Kinase homology domain (KHD) 
This receptor domain, consisting of an approximately 250-amino acid chain and 
located between the transmembrane domain and the catalytic domain, exposes a 
structure conserved in many protein kinases, though no kinase activity has been 
identified. Its function is remained to be fully characterized, however, studies indicate 
that it represses the enzyme activity of the catalytic domain but is also essential for 
the latter’s activation. Furthermore it probably binds ATP (Garbers 1991; Koller, de 
Sauvage et al. 1992; Potter and Hunter 2001; Kuhn 2003). Phosphorylation sites 
within the KHD, mainly serine and threonine, are predicted to be involved in the 
activity state of both GCs (Potter and Garbers 1992; Potter and Hunter 2001; 
Potthast and Potter 2005). The role of this domain in receptor regulation will be 
discussed below. 
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1.2.1.4 Hinge region 
The coiled coil proline-rich hinge region, composed of 41 amino-acids, is proposed to 
be involved in the receptor dimerization process, required for its catalytic 
activation.(Thompson and Garbers 1995; Wilson and Chinkers 1995). As already 
mentioned, deletion of this region will lead to monomeric and inactive catalytic 
domains. 
 
1.2.1.5 Cyclase homology domain (CHD) 
The catalytic subunit at the intracellular tail is considered to resemble the catalytic 
domain of adenylyl cyclases in structure. A crystal structure of the GC domain is still 
unexistent. It appears that the catalytic domain contains two active sites per 
homodimer (Potter and Hunter 2001). Finally, the active catalytic domain converts 
guanosine triphosphate (GTP) into cGMP and pyrophosphates. 
 
1.3 Activation and Regulation of Guanylyl Cyclase-
linked Receptors 
1.3.1 Activation of GC-A and GC-B 
Hypothetically, there exist three states of receptor activity: basal, highly active, and 
desensitized (Potter, Abbey-Hosch et al. 2006). In the basal state the enzymatic 
activity is strictly repressed. Upon ligand binding, a conformational change is 
induced, bringing together the juxtamembrane regions of the receptor’s extracellular 
domain (Labrecque, Mc Nicoll et al. 1999). Via an unknown mechanism, this signal is 
transduced across the membrane and relieves the repression of the KHD on the 
catalytic domain. Thus the latter is allowed to dimerize, exposing two active sites on 
each dimer (Potter, Abbey-Hosch et al. 2006). Ligand binding does not lead to a 
change in the oligomeric state of the receptor (Currie, Fok et al. 1992; Hasegawa, 
Hidaka et al. 1999; Potthast and Potter 2005). 
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Several groups suggested that ATP has a crucial role in this activation process, 
though its exact function remains controversial. Originally seen rather as an inhibitor 
of guanylyl cyclase activity, other studies reported that ATP was essential for both 
GC-A and GC-B activation (Waldman, Rapoport et al. 1984; Winquist, Faison et al. 
1984; Kurose, Inagami et al. 1987; Chinkers, Singh et al. 1991; Marala, Sitaramayya 
et al. 1991; Wong, Ma et al. 1995; Potter and Hunter 1998) .Based on recent studies, 
ATP rather stabilizes both receptors, but does not activate them (Potter, Abbey-
Hosch et al. 2006).  
 
1.3.2 Regulation of GC-A and GC-B 
Cells possess a whole range of mechanisms to regulate their receptors or ligand-
dependant activity. First, the abundance of receptors at the cell surface can be 
controlled genetically, by receptor degradation or by receptor internalization. Another 
mechanism is to control local ligand availability by sequestrating the hormone via a 
clearance receptor or by ligand degradation. Yet, none of these mechanisms would 
affect the responsiveness of each receptor to its ligand, but the responsiveness of 
the cell itself (or at least of a cell’s microdomain). A further mechanism used by cells 
to regulate their receptors is the modulation of the receptor’s responsiveness itself.   
The states of the hormone-responsiveness of both GC-A and GC-B are regulated 
primarily by phosphorylation / dephosphorylation (Potter and Garbers 1992; Potter 
and Hunter 1998; Kuhn 2003; Potthast and Potter 2005). Moreover, these receptors 
are apparently not down-regulated by internalization (Fan, Bryan et al. 2005). 
 
1.3.2.1 Receptor phosphorylation 
Phosphorylation and dephosphorylation is seen as a general mechanism within cells 
to regulate cellular protein activities. The tools of this control mechanism are kinases 
and phosphatases which provide the cell the ability to adapt to different physiological 
changes (Mumby and Walter 1993).  
Accordingly, receptors can alter their activation states depending on the degree of 
phosphorylation. As well known, G-protein coupled receptors are active in a 
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dephosphorylated state, whereas ligand binding induces desensitization through G- 
protein receptor kinases (Lefkowitz and Caron 1986). The studies of several groups 
revealed that natriuretic peptide receptors are regulated by phosphorylation as well. 
GC-A and GC-B, expressed in HEK293 cells, show a decreasing guanylyl cyclase 
activity during prolonged incubation with ANP or CNP, respectively. This effect 
correlates with and is explained by dephosphorylation (Potter and Garbers 1992; 
Koller, Lipari et al. 1993; Joubert, Labrecque et al. 2001). Thus, natriuretic peptide 
receptors are regulated in a different manner than G-protein coupled receptors. It is 
thought that GC-A and GC-B are fully phosphorylated in their basal activity state, 
meaning they are most responsive to ligand-dependent stimulation. 
 
For  GC-A, six residues within the KHD were reported to be phosphorylated, four 
serine and two threonine residues. The identified positions are Ser-497, Thr-500, 
Ser-502, Ser-506, Ser-510 and Thr-513. The lack of four or more of these phosphor 
acceptor sites results in a complete unresponsiveness of the receptor to hormone 
stimulation (Koller, Lipari et al. 1993; Potthast and Potter 2005; Potter, Abbey-Hosch 
et al. 2006). GC-B possesses five residues which upon phosphorylation enhance 
receptor activity. The identified sites are Thr-513, Thr-516, Ser-518, Ser-523 and 
Ser-526, also located within the KHD (Potter and Hunter 1998). Reports indicate that 
a mutation of any of these residues to alanine reduces receptor phosphorylation and 
accordingly its enzymatic activity (Potthast and Potter 2005). Unlike GC-A, which is 
totally unresponsive to ANP in a completely dephosphorylated state, GC-B could be 
still stimulated in the same state (Potthast and Potter 2005). 
 
1.3.3 Homologous desensitization 
Despite enhanced production and secretion of ANP under conditions of atrial 
hypertension and cardiac insufficiency ANP-dependent GC-A effects are markedly 
attenuated. Thus, understanding the mechanisms involved in down regulation of GC-
A (and GC-B) during prolonged exposure to their ligands could have important 
consequences from a pathophysiological and clinical point of view. 
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As reported by several groups, prolonged ligand-receptor interactions unleash a 
signaling cascade resulting in receptor dephosphorylation and desensitization 
(Foster, Wedel et al. 1999; Kuhn 2003; Potter, Abbey-Hosch et al. 2006).  
Desensitization caused by the physiological ligand of a receptor is generally called 
homologous desensitization. The conformational change triggered by ligand binding 
leads to the following events: the inhibitory effect of the KHD is abolished, then an 
increased dissociation rate decreases the extracellular domain’s affinity for natriuretic 
peptides (Jewett, Koller et al. 1993). Finally, a conformational change within the KHD 
results in the exposure of the phosphorylated residues to a phosphatase. At the end, 
the receptor is dephosphorylated and less responsive to further ligand stimulation. 
Although, this model was initially proposed for GC-A it similarly holds for GC-B 
(Potter 1998).  
The model for homologous desensitization is illustrated schematically in Figure 2. 
 
 
1.3.4 Heterologous desensitization 
Any mechanism that results in reduction of receptor activity not due to sustained 
agonist exposure is defined as heterologous desensitization. Signaling by 
substances such as angiotensin II, endothelin or vasopressin can similarly facilitate a 
reduction of receptor responsiveness of membrane-linked guanylyl cyclases (Potter 
and Garbers 1994). The vasoconstricting factors such as angiotensin II, endothelin 
and vasopressin induce GC-A desensitization via stimulation of protein kinase C 
(PKC) (Nambi, Whitman et al. 1986; Haneda, Kikkawa et al. 1991; Jaiswal 1992). 
Inositol triphosphate-calcium pathway contributes to GC-B desensitization, 
suggesting that arginine vasopressin-dependent elevated calcium concentration 
within rat aortic smooth muscle cells reduce GC-B activity (Abbey and Potter 2002). 
PKC-independent desensitization of GC-B can be induced by lysophosphatidic acid 
(LPA) and sphingosine-1-phosphate (S1P) (Abbey-Hosch, Cody et al. 2004; 
Potthast, Abbey-Hosch et al. 2004). S1P was shown to play a desensitizing role in 
transfected NIH3T3 fibroblasts and A10 vascular smooth muscle cells, whereas LPA 
Introduction 
___________________________________________________________________ 
18
reduces GC-B activity in NIH3T3 cells and GC-A activity in MA10 Leydig cells 
(Muller, Cortes-Dericks et al. 2006).  
 
 
 
 
 
 
Figure 2: Hypothetical model of GC-A activation and homologous desensitization  
In the basal state, GC-A is phosphorylated on serine and threonine residues within the kinase 
homolgy domain (A). ANP binding to the highly phosphorylated but inactive receptor (in the presence 
of ATP) results in a conformational change that relieves the repression of the KHD on the guanylyl 
cyclase domain (red). This process permits the dimerization of the cyclase domain resulting in its 
enhanced cyclase activity (B). Upon sustained exposure to ANP, dephosphorylation is stimulated and 
ANP dissociates (C). The receptor is now dephosphorylated and thus unresponsive towards further 
ANP stimulation. This process is called homologous desensitization. Phosphate is indicated by P in 
small circles (Kuhn 2003).  
 
A B C 
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1.4 Signaling pathways 
The link between ligand-dependent receptor activation and the cellular responses are 
molecules referred to as second messengers. This term was initially formulated after 
the discovery of 3’,5’ cyclic adenosine monophosphate (cAMP) and extended onto 
further molecules that transform receptor activation into cell response.  
Activation of natriuretic peptide receptors GC-A and GC-B results in enhanced 
synthesis of cGMP. This cyclic nucleotide, first described in 1963 acts as a second 
messenger in multiple signaling pathways (Lucas, Pitari et al. 2000).  
Playing a vital role in processing intracellular information, elevation of intracellular 
cGMP results in modulation of several target proteins, involved in downstream 
signaling events. These target proteins are mainly cGMP-regulated 
phosphodiesterases (PDEs), cGMP-gated ion channels and cGMP-dependent 
protein kinases, (Corbin and Francis 1999; Francis and Corbin 1999).  
Since cGMP is produced by different soluble and membrane-linked guanylyl 
cyclases, which are co-expressed by many cell types, its production and function is 
compartmentalized (Kuhn 2004; Piggott, Hassell et al. 2006).  
 
1.4.1 cGMP-dependent protein kinase (PKG) 
The most important target protein of cGMP seems to be the cGMP-dependent 
protein kinase, known as PKG. This enzyme exhibits crucial functions in cGMP-
dependent cellular signaling pathways (Yuasa, Omori et al. 2000). PKG is a dimer 
consisting of two identical monomers, each containing two sites: a catalytic domain 
and a regulatory domain (Francis and Corbin 1999; Pfeifer, Ruth et al. 1999). cGMP-
binding transforms the protein into an active enzyme that phosphorlyates other 
proteins and thus induces physiological effects such as relaxation of vascular smooth 
muscle cells, bronchodilatation, inhibition of cell proliferation and platelet aggregation 
(Lohmann, Vaandrager et al. 1997; Francis and Corbin 1999). 
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Figure 3: Cellular target proteins of cGMP 
Both GC-A and GC-B convert GTP into cGMP upon natriuretic peptide activation. Increased cGMP 
modulates the activity of target proteins such as cGMP-regulated phosphodiesterases (PDEs), cGMP-
dependent protein kinases (PKG) and cGMP-controlled ion channels. These target proteins in turn are 
involved in a variety of physiological processes in the nervous, the cardiovascular and the 
gastrointestinal systems as well as the kidney, bone and other tissues.  
 
 
Two types of PKG have been identified, namely PKG I and PKG II. The former is 
found predominantly in cytoplasm whereas the latter is a membrane-bound protein. 
PKG I can be further subdivided into two isoforms: PKG I-α and PKG I-β. These 
isoforms differ only in their N-terminal sequence and exhibit different affinities for 
cGMP (Wall, Francis et al. 2003). Interestingly, one study indicates that ANP-
dependent cGMP elevation stimulates the recruitment of PKG I from the cytoplasm to 
the plasma membrane. This rebound effect leads to the anchoring of PKG to GC-A 
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and is suggested to represent a mechanism for compartmentation of cGMP signaling 
(Airhart, Yang et al. 2003). 
 
1.4.2 cGMP-regulated phosphodiesterases (PDEs) 
PDEs comprise a large family of structurally related enzymes that hydrolyze cyclic 
nucleotides into the inactive nucleoside 5’-monophosphates. 
The PDE superfamily is classified into 11 families, namely PDE1-PDE11, based on 
amino acid sequences, substrate specificities, regulatory properties, pharmacological 
properties and finally tissue distribution (Dousa 1999; Soderling and Beavo 2000). 
PDEs have different substrate specificities. Some are cAMP-selective (PDE 4, -7 and 
-8), and others are cGMP-selective (PDE 5, -6 and -9). There are also PDEs that can 
hydrolyze both cAMP and cGMP (PDE1, -2, -3, -10 and -11). The cAMP-degradation 
by PDE3 is inhibited by cGMP through competition to the catalytic site. Although 
PDE2 can hydrolyze both cyclic nucleotides, binding of cGMP to the regulatory 
domain increases cAMP affinity and hydrolysis. These mechanisms allow for cross-
regulation of the cAMP and cGMP pathways (Mehats, Andersen et al. 2002). PDE 
enzymes are often targets for pharmacological inhibition due to their unique tissue 
distribution, structural properties, and functional properties (Jeon, Heo et al. 2005). 
The introduction of sildenafil, a drug designed to inhibit PDE5 and thus to prevent the 
degradation of intracellular cGMP, is used to treat male erectile dysfunction and 
pulmonary hypertension. Ultimately, PDEs control the level of second messengers 
and thus modify their access to target proteins. 
 
1.4.3 Cyclic nucleotide-gated ion channels (CNG) 
Cyclic nucleotide-gated ion channel is any ion channel that opens in the presence of 
cyclic nucleotides. Thus, binding of cGMP to its target ion channel may lead to 
changes in membrane potential. The mammalian visual system contains the most 
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famous member of this family, located within the outer membrane of retinal 
photoreceptor cells. The channels are open and allow positively-charged ions to flow 
into the cell, causing depolarization. CNGs play also a key role in the olfactory 
system (Fesenko, Kolesnikov et al. 1985; Nakamura and Gold 1987). They have also 
been detected in many other tissues, including heart, kidney, testis, lung, skeletal 
muscle, and the colon (Kaupp and Seifert 2002; Brown, Strassmaier et al. 2006). 
Despite their well described role in sensory tissue, their physiological function in 
other tissues remains poorly understood. However, this study will mainly focus on the 
first two described effectors of cGMP, the PKG and the PDEs. 
 
1.5 Aims of the study 
 
1.5.1 Background 
Many studies have provided evidence for regulation of natriuretic peptide receptor 
activity by homologous (and heterologous) desensitization, and that this 
desensitization is based on receptor dephosphorylation reactions. However, crucial 
questions remain to be addressed. For example, the kinase(s) and phosphatase(s) 
acting at the receptor molecules have not yet been identified. Moreover, the signaling 
mechanism(s) responsible for re-sensitization/phosphorylation are unknown. In 
addition, it is still unclear whether desensitization pathways are affected in a cell 
type-specific manner.  
One important further question concerns the receptor specificity of such reactions. To 
address this item, Cortes-Dericks investigated homologous desensitization of 
natriuretic peptide receptors in pituitary αT3-1 cells, which endogenously co-express 
ANP (GC-A) and CNP (GC-B) receptors (Muller, Cortes-Dericks et al. 2006). These 
studies revealed that ANP pre-treatments induced desensitization of GC-A, while 
pre-exposure of cells to CNP failed to elicit desensitization of GC-B. Since both 
receptors produced large amounts of the (common) second messenger cGMP in 
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response to ligand binding, it was of interest to examine whether agonist-induced 
increases in cellular cGMP could affect the activity of the other receptor each. Data 
showed that stimulation of GC-A had no effect on GC-B activity. However, and most 
surprisingly, CNP-induced stimulation of GC-B resulted in strongly enhanced activity 
of GC-A. These findings uncovered for the first time a mechanism by which a 
membrane guanylyl cyclase receptor becomes sensitized rather than desensitized. 
Further studies revealed that the CNP-induced sensitization of GC-A is blocked by 
cAMP-dependent protein kinase (PKA) inhibitors, indicating that PKA acts as an 
essential component in the signaling pathway.  
 
 
1.5.2 Experiments with rat aorta 
 
The observed sensitization of GC-A by CNP/GC-B signaling in pituitary αT3-1 cells 
raised the significant question whether such a regulation may take place also in other 
cell types co-expressing GC-A and GC-B. A particularly interesting cell type in this 
regard is the vascular smooth muscle cell. ANP signaling plays a pivotal role for 
regulating vascular contraction/relaxation via cGMP-mediated pathways (Pandey 
2005), and several reports suggested the expression of both ANP (GC-A) and CNP 
(GC-B) receptors in smooth muscle cells of the aorta (Nagase, Katafuchi et al. 1997; 
Steinmetz, Potthast et al. 2004; Potter, Abbey-Hosch et al. 2006). The latter 
conclusion, however, was primarily based on investigations of receptor gene 
expression, and convincing data indicating co-expression at the protein level have 
not yet been provided. 
Thus, the first goal of my investigations was to examine the protein expression of 
GC-A and GC-B in cells of the rat aorta. In the case of evidence for co-expression in 
vascular smooth cells, the aorta could be used in a proper way by functional 
approaches (e. g., tension recording, measuring of ligand-induced cGMP production) 
to address the following key questions:  
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1. Can CNP pre-exposure enhance the vasorelaxing potency of ANP? 
2. Can CNP pre-exposure increase ANP-elicited cGMP production? 
 
In addition, and partially dependent on the results obtained, further studies should 
clarify the following items: 
 
3. If CNP pre-exposure in fact evokes sensitization of GC-A: Is this reaction (like 
in αT3-1 cells) mediated by PKA? 
4. Considering conflicting data in the literature: Can stimulation of either GC-B 
(by CNP) or NPR-C (by c-ANF) also induce vasorelaxation? 
5. Is the activity of GC-A in vascular smooth muscle cells regulated by 
homologous desensitization? Which kinase(s) mediate(s) this reaction? 
6. Can CNP signaling counteract homologous desensitization of GC-A? 
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Figure 4: Overview of underlying questions for experiments with rat aorta 
Studies are designed to examine (a) whether prolonged exposure to ANP results in desensitization of 
GC-A, (b) whether desensitization can be relieved by a CNP/GC-B-dependent pathway, (c) if specific 
molecules can be identified as co-actors in this process.
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2 Materials and Methods 
 
2.1 Materials 
 
2.1.1 Wistar rats 
Thoracic aortae were derived from healthy adult male Wistar rats (~250g), 
kindly provided by the Institute of Physiology, Justus-Liebig-Universität, 
Gießen. The animals were housed in cages, were fed a standard diet and had 
access to tap water ad libitum.  
 
2.1.2 Reagents, solutions and substances 
 Solutions used 
 Bouin’s Fixative     Saturated picric acid 15ml 
        Formaldehyde     5ml 
        Glacial acetic acid    1ml 
 Minimum Essential Medium (MEM, 
containing Earle’s salts and L-glutamine): 2mM L-glutamine 
5.56 mM glucose 
1.8 mM CaCl2 
0.813 mM MgSO4 
26.19 mM NaHCO3 
117.24 mM NaCl 
5.33 mM KCl 
1.09 mM NaH2PO4 
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Hank’s Balanced Salt Solution (HBSS, 
 containing calcium and magnesium): 5.56 mM glucose 
       1.26 mM CaCl2 
       0.493 mM MgCl2 
       0.407 mM MgSO4 
       0.441 mM KH2PO4 
       4.17 mM NaHCO3 
5.33 mM KCl 
137.93 mM NaCl 
0.338 mM Na2HPO4 
Homogenizing buffer:   50mM Tris-HCl, pH 7.5 
      1mM EDTA 
      1mM Dithiothreitol (DTT) 
0.1 mM Phenyl-methyl-sulfonyl-
fluoride (PMSF) 
4x Separating gel buffer:   0.375 M Tris-HCl, pH 8.8 
      0.1% (w/v) SDS 
4x Stacking gel buffer:   0.5 M Tris-HCl, pH 6.8 
      0.1% (w/v) SDS 
PAGE buffer:    0.025 M Tris-HCl, pH 8.4 
      0.192 M glycine 
      0.1% (w/v) SDS 
3x SDS PAGE sample buffer:  0.375 M Tris-HCl, pH 6.8 
      0.2 M DTT 
      15% (w/v) SDS 
      20% (v/v) glycerine 
      0.6 mg/ml bromphenol blue 
Tank blotting transfer buffer:  100 mM Tris base 
      193 mM glycine 
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10x TBS buffer:    200 mM Tris base 
      1.37 M NaCl 
      adjust pH to 7.6 
TBST tween buffer:    1x TBS buffer + 0.05% Tween 20 
Blocking buffer:  1% Amersham blocking reagent 
0.1 M maleic acid/NaOH 
      0.15 M NaCl 
adjust pH to 7.5 prior to addition of 
0.005% thimerosal 
 Antibody dilution buffer:   90% TBST 
       10% blocking buffer 
       0.005% thimerosal 
 E-PBS buffer :    0.1 M Na2PO4  
       0.15 M NaCl 
       0.005 M EDTA 
       0.2% BSA 
       0.01% thimerosal 
       pH 7.0 
 Substrate buffer:    4.8 M Na-acetate 
       0.24 M citric acid 
 Wash solution:    0.02% Tween 20 in H2O  
       0.5% NaCl 
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Table 2: Substances and concentrations used 
 
Substance Supplier Concentrations used (M) 
Norepinephrine Hoechst Marion Roussel 1x10-5 
Atrial natriuretic peptide, 
(ANP) 
Bachem 5x10-7 
C-type natriuretic peptide, 
(CNP) 
Bachem 5x10-7, 1x10-7, 5x10-8 
Rp-cAMPS (PKA inhibitor) BioLog 3x10-5 
(Cys18)-atrial natriuretic 
factor (4-23) amide, cANF 
(NPR-C agonist) 
Bachem 5x10-7 
3-Isobutyl-1-Methyl-
Xanthin (IBMX) 
Sigma 2x10-4 
Rp-8-Br-cGMPS (PKG-
inhibitor) 
BioLog 1-5x10-6 
HS-142 (Inhibitor of both 
GC-A and GC-B) 
Mr. Yuzuru Matsuda, 
Tokyo Research 
Laboratories 
10-3 
8-br-cAMP (8-bromo-
cyclic- adenosine 
monophosphate) 
Biolog 10-3 
125I-ANP Amersham 1x10-9 
125I-CNP Amersham 3x10-9 
 
2.2 Methods 
 
2.2.1 Vessel preparation 
Rats were anesthetized with isoflorane (Baxter) and subsequently sacrificed by 
cervical dislocation. The abdomen and thorax were opened with a midline incision 
and both the heart and the aorta were carefully excised. Aortae were dissected from 
the heart and placed immediately in HBSS at 4° C. 
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Depending on the experiments intended, vessels were either used for 
immunohistochemistry (2.2.2), protein extraction (2.2.3), cut into rings for organ bath 
experiments (2.25) or dissected longitudinally for cGMP measurement (2.2.6) 
  
2.2.2 Immunohistochemistry (IHC) 
Immunohistochemistry visualizes the localization of proteins in cells and tissues. For 
that purpose tissues are fixed and cut into thin slices prior to incubation with primary 
antibodies in question. The binding sites of these antibodies become detectable by 
usage of secondary antibodies that produce visible reaction products.  
In this study, both paraffin and cryostat sections were used.  
For former sections, aortae were fixed in Bouin’s fixative and then dehydrated in 
ascending ethanol concentrations. Afterwards tissues were embedded with paraffin 
at 60° C by using a tissue processor (Leica TP 1020, Bensheim, Germany). Sections 
of 6 µm were sliced with a microtome (Autocut 1140, Reichert-Jung) and mounted 
onto chrome gelatine-coated slides followed by a drying period at 37° C overnight. 
Subsequently sections were deparaffinised in descending ethanol concentrations and 
rehydrated with H2O. In order to block endogenous peroxidase activity, sections were 
treated with 1.2% H2O2 in methanol for 30 min and then washed with phosphate 
buffered saline (PBS) for another 15 min. Sections were blocked with 2% swine non-
immune serum. After incubation with primary antibodies (see table below) overnight 
at 4° C, sections were washed with PBS for 3x10 min. Sections were treated with 
anti-rabbit IgG-biotin, (swine 1:250 in PBS) for 60 min at room temperature and 
washed afterwards 2x10 minutes with PBS. A combination of the peroxidase 
antiperoxidase (PAP) technique with the avidin-biotin-peroxidase complex method 
was employed, visualizing peroxidase activity by the nickel-glucose oxidase approach 
(Middendorff, Muller et al. 2002): 
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For cryosections, rat aortae were embedded in Tissue Tec (Sakura, Torrance, CA, 
USA) and frozen in 2-methylbutane (Fluken) over liquid nitrogen. Sections of 10µm 
were cut with a cryostat (Leica CM 1900, Bensheim, Germany). Slices were mounted 
onto chrome gelatine-coated slides and fixed by 4% paraformaldehyde in PBS for 20 
min, followed by 10 min washing in H2O and drying for one h at room temperature. 
After preincubation with 2% normal goat serum in PBS, primary antibodies directed 
against GC-A or GC-B (see table below) were applied and incubated at 4° C 
overnight. Sections were washed with PBS for 2x10 min and then incubated with 
Cy3-conjugated secondary goat-anti-rabbit-IgG-antibody (Dianova) for 1 h at room 
temperature in darkness. After washing with PBS, sections were analysed. 
For negative controls, sections were used, in which primary antibodies were replaced 
by PBS.  
Sections were viewed with a fluorescence microscope (Axioskop2 plus, Zeiss, 
Germany). Micrographs were taken by a digital camera (Axiocam Mrc, Zeiss) and 
edited with manufactor’s software (Axiovision Release 4.6.3, Zeiss). 
 
 
Table3: Antibodies used in immunohistochemistry 
Primary Antibody Host Dilution Manufacturer 
GC-A Rabbit 1:50 FabGennix 
GC-A Rabbit 1:50 Kuhn, University of 
Würzburg 
GC-B Rabbit 1:100 FabGennix 
 
 
2.2.3 Protein extraction 
Proteins were extracted from isolated aortas. The surrounding connective tissue was 
either removed or not. Frozen in liquid nitrogen, tissues were grinded with a mortar, 
suspended in homogenizing buffer and then homogenized in a Potter-Elvehjem 
homogenizer by ~10 strokes. To remove cell debris and nuclei, the resulting 
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homogenates were centrifuged for 8 min at 3,000 x g at 4° C (Eppendorf 5804 R, 
Hamburg, Germany). The supernatant fractions containing cytosol and particulate 
fractions were re-centrifuged at 100,000 x g for 30 min at 4° C using an 
ultracentrifuge (Ultra Pro 80, Savall, Wilmington, DE, USA). Resulting pellets, 
containing membranes, were resuspended with 50 mM Tris-buffer, pH 7.5. Protein 
concentration was determined according to Bradford (Bradford, 1976) using Bio-Rad 
Protein Assay Kit (Bio-Rad Laboratories, Inc., Munich, Germany) by means of BSA 
(fraction V) as standard. 
 
2.2.4 Western Blot 
2.2.4.1 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE is a method to separate proteins based on their size. Proteins are 
maintained in a denatured state after treatment with reducing agents to remove 
secondary and tertiary structure (including disulfide bonds). Sample proteins become 
covered in anionic detergent SDS and move to the positively charged electrode 
through the acrylamide mesh. The migrations velocity is dependent on the protein 
size. 
 
In my studies, SDS-Page was performed according to Laemmli (1970). 
Separating gels were pipetted carefully between glass plates avoiding formation of 
air bubbles. Gel solutions were overlayered with 400 µl butanol and allowed to 
polymerize at room temperature overnight. 
The following day, butanol was removed and combs were inserted between glass 
plates to enable the formation of wells. Stacking gel solutions were pipetted down on 
the top of the separating gel. After polymerization (60min) combs were removed and 
the wells were filled with PAGE buffer using a syringe. Samples were boiled at 100° 
C for 2 min and subsequently chilled on ice for 20 seconds followed by loading the 
samples. 
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Electrophoresis was performed in Hoefer SE 600 units (Hoefer Scientific, 
Instruments, San Francisco, CA, USA). An initial power of 13 W was applied until 
samples have reached separating gel. Thereafter the electrophoresis was continued 
at 17 W for 2 h. Molecular weight standards (Sigma) were used as size references 
(see table 4). 
 
Table 4: Reference proteins for SDS-PAGE 
Protein Molecular Weight 
Myosin, porcine 200.000 
B-Galactosidase, E. coli 116.000 
Phosphorylase b, rabbit muscle 97.000 
Albumin, bovine 66.000 
Albumin, chicken egg white 45.000 
Carbonic Anhydrase, bovine erythrocytes 29.000 
 
 
 
2.2.4.2 Protein transfer to membranes (blotting) 
Size-separated proteins from gels were transferred to nitrocellulose membranes 
(Hybond ELL, Amersham Biosciences, Germany) using tank blotting transfer buffer. 
Membranes and filter paper were cut according to the size of the gel and equilibrated 
in transfer buffer. The gel-blot-package, consisting of 2 sheets of 3MM-Whatman 
paper (Maidstone, UK), the gel, the membrane and another 2 sheets of Whatman 
paper were laid onto a glass plate. By rolling carefully a glass pipette on top of the 
blots any bubbles that may have been stuck underneath the gel, were removed. The 
blots were mounted in holder cassettes which were installed in the blot tank filled with 
transfer buffer. 
Electroblotting was carried out at 29 V at 4° C overnight. Blots were stained with 
Ponceau S for ten min in order to control the efficiency of protein transfer. 
Membranes were rinsed with H2O for 2 min, scanned for digitalized documentation 
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and thereafter blocked in blocking buffer for 2 h in a shaking apparatus (PMR-30, 
Grant-Bio, Cambridgeshire, UK). Prior to immunostaining, membranes were shaken 
in TBST for 5 min.  
 
2.2.4.3 Immunostaining of membranes 
After blocking, primary antibodies (see table 5) diluted with antibody dilution buffer 
were added and incubated for 1 h at room temperature. Subsequently membranes 
were washed (3x5 min) in TBST and then incubated with peroxidase-linked 
secondary antibodies for one h at room temperature. After another washing series in 
TBST as before, binding of the antibody was visualized using enhanced 
chemiluminescence (ECL) according to manufacturer’s protocol (Amersham, GE 
Healthcare, Buckinghamshire, UK). Blots were wrapped with a plastic foil, placed into 
a film cassette (Hypercassette, Amersham, Biotek, UK) and exposed to x-ray films 
(Fuji Medical X-Ray, 18x24) up to 5 min. Films were developed by incubation in 
appropriate agents (Agfa, G138i) for 2 min and fixed (Agfa, 334i) for 1 min. Finally 
the films were rinsed with water and hanged up for drying. 
 
Table 5: Primary antibodies used in immunoblotting 
Primary Antibody Dilution 
GC-A (Kuhn) 1:500 
GC-A (FabGennix) 1:500 
GC-B (FabGennix) 1:500 
 
Table 6: Secondary antibodies used in immunoblotting 
Secondary Antibody Dilution Manufacturer 
Peroxidase-conjugated 
goat-anti-rabbit IgG 
1:2000 Pierce Biotechnology 
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2.2.5 Affinity cross-linking 
This method enables detection of receptors after cross linking with their radioactively 
labelled ligands (Muller, Hida et al. 2009).   
Aorta membrane preparations were incubated with either 125I-ANP (1 nM) or 125I-
CNP (3 nM) in total volumes of 40 µl of 20 mM HEPES buffer, pH 7.5, containing 5 
mM MgCl2, 125 mM NaCl, and the protease inhibitors parahydroxymercury benzoate 
(60 µg/ml), bacitracin (1 mg/ml), bestatin (50 µg/ml), phosphoramidon (50 µg/ml), and 
1.10-phenanthroline (1 mM) for 15 min at 20°C. Samples were then irradiated in the 
dark for 10 min with UV light (peak wavelength 302 nm) followed by chilling and 
immediate addition of 20 µl of 3X SDS-PAGE sample buffer. Prior to analysis by 
SDS-PAGE under reducing conditions according to Laemmli (1970) in 7% 
polyacrylamide separation gels, samples were boiled for 3 min. For visualization of 
molecular weight marker proteins (Sigma, SDS-6H), gels were stained with 
Coomassie brilliant blue, then dried in a Gel dryer (Bio-Rad, model 583, USA) and 
exposed for 5 days to X-ray film (Kodak XAR-5) between intensifying screens at -
70°C. 
To confirm the identity of GC-A and GC-B, reactions were also performed in the 
presence of an excess (1 µM) of unlabelled ANP or CNP, respectively. 
 
2.2.6 Isometric tension studies 
Isometric tension studies in organ baths enable sensitive measurements with the 
intact biological structures ex vivo. Contraction of vessels is detectable by an 
increase in force transduction, whereas relaxation correlates with decreasing force. 
For isometric tension studies in the organ chamber, a ring of approximately 3mm 
length was excised gently off the thoracic part of the vessel. In order to avoid holes in 
the inner wall of the ring, segments were cut always between the outlets of the aorta. 
All connective tissue and periadventitial fat were removed from the segment with 
care under microscopic view while harming of the endothelium was avoided.  
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The rings were suspended in a 15 ml organ bath using two stainless-steel hooks 
placed vertically through the lumen. The lower hook was fixed, while the upper one 
was connected to isometric force recording transducer (SG4-90, Hugo Sachs, 
Freiburg, Germany). The output of the transducer was digitized at 1 Hz by using a 
Metrabyte DAS 1202 interface (Keithley Instruments, Cleveland, OH). 
Simultaneously, isometric force was recorded analogue on a chart recorder (200 E, 
Linseis, Selb, Germany). 
Each organ bath contained 15 ml MEM, continuously gassed with carbogen (95% O2 
and 5% CO2) to provide oxygenation and pH stability. 
Prior to drug addition the rings were stretched to a preload tension of 10 mN. It was 
allowed to equilibrate for 1-2 h and to attain a steady-state resting tension to prevent 
stretch-induced contractions (Mewe, Bauer et al. 2006).  
Data collection was carried out by using a DOS program developed by P. Bassalay 
(Institute of Physiology, UKE, Hamburg, Germany). Further data processing was 
performed with Sigma Plot 5.0 (SPSS, Chicago, IL). 
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Figure 5: Setting of isometric tension studies 
Aortic ring was suspended into medium-filled and carbogen-gassed organ bath and mounted between 
two stainless steel hooks, one fixed, the other connected to a force transducer. Force, exerted by the 
tension of the rings, was digitized via computer and simultaneously recorded on an analogue chart 
recorder. The temperature of the organ bath was maintained at 37°C.  
 
After the resting tension of aortic rings reached a steady state, a trial of 3-5 minutes 
was recorded before experimental treatments. Experiments started with a 
precontraction induced by 1x10-5M norepinephrine.  Once maximum responses had 
developed and a plateau of contraction had been reached, relaxation was initiated by 
adding natriuretic peptides, response curves for ANP and CNP were then recorded.  
Relaxation was expressed as percentage of the maximum steady-state tension 
(100%) after initial contraction. 
Between experiments organ chambers were rinsed several times with deionised 
water to wash out agents from previous experiments and to avoid accumulation of 
metabolites. 
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2.2.7 Measurements of cGMP production 
Aortae were freed from surrounding tissue, and all outlets were cut off directly along 
the vessel’s wall. Purified vessels were divided into 2 stripes of similar width and a 
moist mass of approximately 2-4 mg. In each case, one of these stripes served as 
control during following experimentation. The stripes were stored in MEM (4° C) until 
being used for experiments. 
Stripes from 1-4 aortae were used per experiment, each divided into treatment 
groups A and B. 
Both groups were washed again and pre-incubated in MEM for 5 min at 37° C in a 
heat block. After short (3 sec) centrifugation, medium was removed with a pipette.  
To induce cGMP generation, samples were treated with ANP (or CNP) for 20 or 30 
min at 37° C in the presence of 0.2 mM 1-methyl-3-isobutyl-xanthine (IBMX, a 
phosphodiesterase inhibitor used to avoid cGMP degradation).  
In some experiments, samples were preincubated once or twice for predetermined 
periods with different substances (see protocols below). In those cases, medium was 
removed again after preincubation as described before and the second incubation 
was carried out accordingly.  
Reactions were terminated by chilling. The medium (as well as the vessel stripes) 
were removed and frozen in liquid nitrogen and stored at -80° C cGMP 
measurements by means of a commercial ELISA. 
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Figure 6: Experimental design for measurements of ANP-induced cGMP generation by 
of rat aorta 
Aortae were dissected longitudinally, one half assigned to group A, the other half to group B. After pre-
incubation in MEM for 5 min at 37°C, samples were pre-treated with different agents.  Finally samples 
were incubated with ANP to elicit cGMP production. IBMX was added to avoid degradation of cGMP. 
Reactions were terminated by putting tubes on ice. The amounts of cGMP were determined by ELISA. 
 
2.2.7.1 Enzyme-linked-immuno-sorbent-assay (ELISA) 
The amounts of cGMP after different treatments were determined by enzyme-linked-
immuno-sorbent-assay (ELISA). It is based on a competitive double-antibodies 
enzyme immuno assay with solid phase technique. The immunologic reaction takes 
place in goat-anti-rabbit-antibodies-coated wells. The cGMP in the sample competes 
with a biotin labelled cGMP tracer for binding to the (primary) anti-cGMP-antibody. 
Thus, both cGMP-antibody and tracer-antibody complexes are simultaneously bound 
to the surface of the wells via the secondary antibody. In a second step, a 
streptavidin-coupled horseradish peroxidase (HRP) is added, which binds selectively 
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to the tracer-antibody complex. The enzyme activity converts the colourless substrate 
tetramethyl benzidin (TMB) into blue. After adding H2SO4 blue turns into yellow. The 
colour change of the chromogen depends on the amount of enzyme linked to the 
wells and is inversely proportional to the cGMP concentration. 
 
cGMP standards were prepared at the following concentrations: 34.02, 11.34, 3.78, 
1.26, 0.42, 0.14, 0.00 pmol/ml assay buffer (EPBS). Before starting the assay, a 96-
well plate coated with goat-anti-rabbit-antibodies was prewashed with EPBS at room 
temperature. 50 µl of standards and 50 µl of samples were pipetted first, followed by 
50 µl of cGMP-biotin. Finally 100 µl cGMP antiserum was added. The plate was 
incubated in a H2O moistened chamber at 4° C in darkness for 18 h. 
After washing 0.2 ml HRP-Streptavidin was substituted and incubated for 30 min at 
4° C in darkness. Subsequently, well plates were washed 4 times with wash solution 
at room temperature. The substrate solution (250µl TMB) was incubated for 40 min at 
room temperature in darkness. 
Reactions were terminated by addition of 50 µl 2M H2SO4. Plates were measured in 
an ELISA reader (Dynex revelation) at 450 nm. The minimum detection limit was 0.14 
pmol/ml and cross-reactivity with cAMP less than 0.0001%. 
 
2.2.8 Data presentation and statistical analysis 
Data were analysed and presented using Prism 4.00 (GraphPad software Inc., San 
Diego, CA, USA) and Excell (Office XP, Microsoft Inc.). The significance of effects 
was assessed by unpaired t test or 1way ANOVA. Significant effects (P values <0.05) 
are indicated by asterisks. Standard deviations are indicated by vertical bars. 
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3 Results 
Earlier studies revealed a co-expression of the two cGMP-generating natriuretic 
peptide receptors, GC-A and GC-B in αT3-1 cells (Muller, Cortes-Dericks et al. 2006) 
and provided evidence for a regulatory cross-talk between the two receptor signaling 
pathways in this cell (see Introduction). Based on these findings, rat aortic tissue was 
thought to represent an attractive experimental model to investigate whether similar 
regulatory mechanisms are present in the vascular system. 
 
3.1 Characterization of natriuretic peptide receptors 
in vasculature 
 
Although gene expression of natriuretic peptide receptors in the vasculature has 
been reported, reliable data on these receptors at the protein level have not yet been 
published. By means of highly specific antibodies, this study used 
immunohistochemical and immunoblotting approaches to examine the expression of 
GC-A and GC-B in rat aorta. Additionally, affinity cross-linking experiments were 
performed as a further approach for analyzing these proteins and allowed to co-
examine the local expression of the third natriuretic peptide receptor, NPR-C. 
 
3.1.1 Immunohistochemical analysis of GC-A and GC-B expression in rat 
aorta 
 
To examine the distribution of natriuretic peptide receptors in vascular tissue, rat 
aortae were isolated and fixed for immunohistochemical analyses. Both cryosections 
and paraffin sections of rat aortae were incubated with antibodies against GC-A and 
GC-B. While visualization of immunoreactivity in paraffin sections was induced by the 
use of the peroxidase antiperoxidase technique with nickel glucose oxidase 
amplification (Middendorff, Muller et al. 2002), Cy3-conjugated secondary antibodies 
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A 
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B 
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C 
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served to visualize immunoreactivity on cryosections. For specifity controls, 
analogous assays were performed with PBS instead of primary antibodies. 
 
 
Figure 3: Immunohistochemical analysis of GC-A and GC-B expression in 
cryosections of rat aorta 
Rat aorta sections (10µm) were treated with anti-GC-A antibody (A) or anti-GC-B antibodies (B). 
Control incubations with PBS instead of primary antibodies are shown in C. Cy3-conjugated secondary 
antibody served to visualize immunoreactivity. Specific staining is evident in endothelial cells (*) and in 
smooth muscle cells located in the media (I----I). Connective tissue (green arrows) lacks almost 
completely any immunoreactivity. 
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Figure 4: Immunohistochemical analysis of GC-A and GC-B expression in paraffin 
sections of rat aorta 
Paraffin sections (6 µm) were incubated in either the presence (A) or absence (B) of anti-GC-A-
antibodies. A combination of the peroxidase antiperoxidase (PAP) technique with the avidin-biotin-
peroxidase complex method was employed to visualize immunoreactivity. GC-A expression is 
detectable in the intima (i) and media (m), but not in the adventitial connective tissue (a) of the aorta 
(A). At higher magnification (C), staining of endothelial cells (EC, arrow) and smooth muscle cells 
(SMC, arrow) becomes evident. 
 
These studies revealed abundant expression of GC-A (Fig. 3A) and GC-B (Fig. 3B) in 
the vessel’s intima and media, indicating localization in endothelial cells and smooth 
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muscle cells. On the other hand, both receptors are barely detectable in the 
connective tissue surrounding the vessel. Control sections (Fig. 3C) proved the 
specifity of antibody reactions. These findings were confirmed by corresponding 
analyses of GC-A (Fig. 4) and GC-B (data not shown) on paraffin sections. Thus, 
these results obtained clarified the distribution of these receptors in aortic tissue and 
provided strong evidence for co-expressions of GC-A and GC-B in both endothelial 
and smooth muscle cells. 
 
  
3.1.2 Immunoblot analysis of GC-A and GC-B expression in rat aorta 
To further characterize the expression of natriuretic peptide receptors in the 
vasculature, samples of rat aortae were homogenized and analyzed via 
immunoblotting. In these experiments vessels with or without surrounding connective 
tissue were used.  
After separation by SDS-PAGE equal amounts of membrane protein were blotted 
and receptor levels were detected by use of antibodies against GC-A and GC-B (Fig. 
5). These studies revealed a strong expression of both GC-A and GC-B in aortic 
tissue freed of surrounding connective tissue, whereas receptor levels were much 
lower in samples including connective tissue remained low (Fig. 5). The results 
confirmed the immunohistochemical data showing that both receptor types are 
predominantly distributed within the media and intima layers of the vessel and 
localized to endothelial and smooth muscle cells.  
Protein size markers were used to assess the apparent receptor molecular masses. 
Consistent with recent findings (Muller, Hildebrand et al. 2010), GC-A has a size of 
127 kDa in rat aorta. The higher molecular mass of GC-B (130 kDa) is explained by 
an enhanced extent of N-linked glycolization (Muller, Hildebrand et al. 2010) .  
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Figure 5: immunoblot analyses of GC-A and GC-B in isolated rat aortae 
Aortae were isolated from male Wistar rats. Connective tissue was either carefully removed (-) or not 
(+). Samples derived from at least three animals were homogenized and membrane proteins were 
separated by SDS-PAGE and subsequently subjected to immunoblot analyses using antibodies 
directed against GC-A and GC-B respectively. Positions of antigens (arrows) and receptor sizes (in 
kDa) are indicated. Data is a representative of at least three experiments performed.  
 
3.1.3 Affinity labeling of natriuretic peptide receptors, GC-A, GC-B and 
NPR-C, in rat aorta 
 
To further investigate natriuretic peptide receptor expression in rat vascular tissue 
photoaffinity labeling were used. 
Membranes prepared as described above were incubated with radiolabeled ANP (the 
natural ligand to GC-A) or CNP (ligand to GC-B), respectively. Again, vessels with 
connective tissue were compared with those freed of surrounding tissue.  
Receptor expression was analyzed by UV light-induced cross linking followed by 
SDS-PAGE and autoradiography. Several previous studies have proved this method 
to be a reliable approach for detection of NP receptors in tissues (Muller, 
Mukhopadhyay et al. 2004; Muller, Hida et al. 2009; Muller, Hildebrand et al. 2010). 
Consistent with the immunohistochemical and immunoblotting data, these 
experiments demonstrated the presence of GC-A (Fig. 6a) and GC-B (Fig. 6b) in 
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vascular tissue. Membranes prepared from aortae without connective tissue showed 
much higher receptor concentrations then those where connective tissue was not 
removed. These findings confirmed the predominant expression of GC-A and GC-B 
in membranes of endothelial and smooth muscle cells. 
Importantly, cross linking approach also revealed detectable amounts of the third 
natriuretic receptor, NPR-C, which is labeled by both radioligands and migrates at 60 
kDa (Fig. 6a, b). In contrast to GC-A and GC-B, levels of NPR-C are much more 
pronounced in aortae unfreed of surrounding tissue, indicating its predominant 
expression in the connective tissue and rather than in the media and intima layers of 
the vessel. 
 
. 
 
 
 
 
 
 
 
 
 
 
Figure 6: Analysis of natriuretic peptide receptors expression in isolated rat aorta by 
photoaffinity labeling 
 
Equal amounts of membrane protein, containing (+) or derived of (-) surrounding connective tissue  
extracted from rat aortae were incubated  with either 125I-ANP (A) or 125I-CNP (B) in the presence of 
protease inhibitor (see 2.2.4). Receptor/radioligand cross linking was induced by UV irradiation and 
reaction products were resolved by SDS-PAGE and autoradiography. Radiolabelled GC-A (A, 130kDa) 
and GC-B (B, 132 kDa) are indicated by arrows. NPR-C, labeled by both radioligands appears at 
nearly 60 kDa. Bands at 66 kDa marked by asterisks represent unspecifically labeled serum albumin, 
usually present in 125I-labeled peptide solutions. 
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Thus three distinct approaches, namely immunohistochemistry, immunoblotting and 
affinity cross linking, consistently revealed a co-expression of GC-A and GC-B in 
aortic tissue. The obtained results further demonstrate that these receptors are 
predominantly localized in the intima and media layers of the vessel, indicating that 
mainly endothelial cells and smooth muscle cells are the sites of expressions. 
Additionally, data shows a differential distribution of the third natriuretic peptide 
receptors, NPR-C, which is predominantly expressed in cells of the adventitial 
connective tissue surrounding the aorta. 
These studies revealed for the first time on a protein basis, that both receptors are 
co-expressed in aortic tissue, predominantly in endothelial cells and smooth muscle 
cells, while the third natriuretic receptor type, NPR-C, was found mainly in the 
surrounding tissue. 
 
Considering the identified GC-A regulation by GC-B/CNP signaling in αT3-1 cells 
which co-express both receptors, the above results provided and experimental basis 
to examine whether such a cross talk is present and active also in cell types of the 
aorta. 
 
3.2 Isometric tension studies with rat aorta 
After expression of natriuretic peptide receptors has been characterized in rat aorta, 
functional experiments with isolated vessels were carried out in order to assess the 
activities of these receptors by measuring their impact on change in vascular tone. 
Since all three receptors are expressed in rat aorta, with GC-A and GC-B 
predominantly in smooth muscle cells, preliminary experiments served to determine 
which receptor is primarily responsible to mediate vessel relaxation through ligand 
activation. Moreover, the role of the so-called clearance receptor, NPR-C, in 
vasorelaxation was investigated. 
In general, thoracic aortae, obtained from male Wistar rats, were carefully cleaned of 
their fascia. To assure the integrity of the wall, rings were cut only between vessel 
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outlets. Rings were placed in a double-jacketed tissue bath in oxygenated medium at 
37° C, mounted on two stainless-steel hooks, the lower hook fixed while the upper 
one transmitted isometric force via a force transducer. 
After rings were stretched to a preload tension of 10 mN, they relaxed to a steady-
state resting tension after 1-2 hours. Following a trial of 3-5 minutes of resting 
tension, experiments started with addition of norepinephrine (NE) to induce vessel 
contraction. Rings were then treated with vasorelaxant agents once maximum 
response had developed and a stable contraction tension had been reached. 
Degree of relaxation was expressed as the percentage of tension reduction between 
the maximum norepinephrine-induced tension before application of vasorelaxant 
agents and the baseline tension prior to NE administration.  
  
3.2.1 Vasorelaxant potency of ANP 
Following treatment with norepinephrine, aortic rings were exposed in a cumulative 
manner to increasing concentrations (10-9 to 5x10-7 M) of ANP. Single doses were 
given at intervals of 2 minutes or after a stable tension was attained (Fig. 7). 
Significant vasorelaxation was detectable at low ANP concentrations (10% at 10nM) 
and after the final administration of 500 nM, the NE-induced tension was reduced by 
80%. 
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Figure 7: Concentration dependency of ANP-induced vasorelaxation: 
Relaxation of the aorta by increasing concentration of ANP after precontraction with norepinephrine 
(NE) was recorded. The times and concentrations of the agents applied are indicated. 
 
 
3.2.2 Vasorelaxant potency of CNP 
To investigate vasorelaxant effects induced by the CNP receptor, GC-B, analogous 
experiments were carried out with CNP instead of ANP. Again, precontracted aortae 
were treated with increasing peptide concentrations ranging from 10-9 to 5x10-7 M 
(Fig.8). 
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Figure 8: Concentration dependency of CNP-induced vasorelaxation:  
Relaxation of the aorta by increasing concentration of CNP after precontraction with norepinephrine 
(NE) was recorded. The times and concentrations of the agents applied are indicated. 
 
As compared to ANP (Fig.7), CNP was less effective in eliciting vasorelaxation. 
Significant effects were detectable only at relatively high (≥100nM) peptide 
concentrations and the overall reduction of NE-induced vessel tension remained low 
(<30%). Since CNP can interact with GC-A at concentrations ≥ 100nM (Muller, 
Middendorff et al. 2002), these findings raised the possibility that the vasorelaxing 
effects of CNP were due to cross activation of GC-A. 
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3.2.3 Vasorelaxant potency of the NPR-C ligand cANF 
The third member of the natriuretic peptide receptor family is NPR-C, a non-guanylyl 
cyclase receptor, also referred to as natriuretic peptide clearance receptor. In 
addition to its clearance function, NPR-C may also have a signaling role by affecting 
intracellular cAMP levels (Anand-Srivastava, Sairam et al. 1990). To investigate 
whether NPR-C has effects on vascular tone precontracted aortae were treated with 
the synthetic ANP analog, cANF (ANP 4-23), which lacks part of the peptide ring 
structure and represents a selective NPR-C agonist (Muller, Mukhopadhyay et al. 
2004). 
After inducing contraction by norepinephrine, aortic rings were treated with 500 nM 
cANF (Fig. 9). In contrast to ANP and CNP, cANF failed to evoke any vasodilatory 
effects, even at high peptide concentrations.  
These experiments showed that relaxation of precontracted aortic rings is essentially 
induced by ANP/GC-A signaling, whereas effects elicited by the GC-B ligand CNP 
are low and those by the NPR-C agonist cANF completely undetectable. 
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Figure 9: The NPR-C ligand, cANF, does not induce vasorelaxation 
Precontracted aortae were incubated with high concentrations (500nM) of cANF. These treatments did 
not induce any detectable effects. Arrows indicate the times of NE and cANF administrations.  
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Figure 10: ANP-induced relaxation of precontracted rat aorta: 
Precontracted aortae were treated with 500 nM ANP after development of a stable baseline tension. 
Recorded results show an ANP-induced relaxation of 56%. The trace is typical of more than ten 
experiments performed.. 
 
3.2.4 ANP-induced relaxation 
The next experiments served to characterize the ANP induced vasorelaxation under 
defined conditions (induction by 500nM of the peptide). These studies (Fig. 10 shows 
a typical trace) revealed that administration of 500nM ANP to precontracted aortae 
consistently elicits tension reduction in the range of 40-70% (ẋ: 56%, n=13). 
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3.2.5 ANP-induced relaxation after pretreatment with 100 nM CNP 
 
After characterizing the role of GC-A in mediating vasorelaxation by activation 
through ANP (or high doses of CNP) and ruling out any involvement of NPR-C, the 
next experiments were designed to scrutinize a possible role of GC-B as a regulator 
of its cognate receptor GC-A. To address this issue, precontracted aortic rings were 
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incubated for 15 minutes with CNP (100nM) prior to the addition of ANP (500nM). 
Under these conditions, the finally induced relaxation was generally more 
pronounced (ẋ: 71%) than in control assays without CNP pre-exposure (ẋ: 56%, 
n=13; Fig. 11). 
 
  
        
 
Figure 11: ANP-induced relaxation increases in response to pre-incubation with CNP:   
Precontracted aortic rings were treated with ANP (500nM) in either the absence (control) or presence 
of CNP (100nM).CNP was added 15 minutes before ANP. CNP treatments resulted in an intensified 
relaxation (ẋ: 71%). This effect was significant (*P<0.05). Values are mean ± SD from 13 or 5 
experiments respectively.  
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3.2.6 ANP-induced relaxation after pretreatment with 50 nM CNP 
 
The above experiments have demonstrated that pretreatment with 100nM CNP 
significantly enhanced the degree of vasorelaxation elicited by subsequent 
administration of ANP.  
Considering the findings in αT3 cells, where CNP treatment enhances the hormone-
sensitivity of GC-A (Introduction), these results would lead to the conclusion, that the 
ANP receptor GC-A was more active in the presence of CNP. However, since CNP at 
100nM per se elicits a vasorelaxation by 10% (Fig.8), such an interpretation 
remained questionable. 
In order to avoid any direct effects of CNP on vascular tone, analogous experiments 
were carried out with 50 nM CNP, a concentration shown to be ineffective in eliciting 
tension reduction (Fig. 8). Remarkably, these studies revealed that pretreatments 
with 50nM evoked even higher increases in vasorelaxation than those with 100nM 
(Fig.12). The resulting mean relaxation amounted 89% as compared to 71% in the 
case of 100nM. A typical trace of such experiments is shown in Fig. 13. Thus, the 
letter findings provided strong evidence that CNP/GC-B signaling enhances the 
agonist-dependent activity of GC-A not only in αT3 cells but also in smooth muscle 
cells of the aorta. The striking observation that 100nM CNP was less effective than 
50nM may be explained by CNP binding to GC-A at the former concentration, leading 
to a certain degree of receptor desensitization. 
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Figure 12: Dose-dependent effect of CNP on ANP-induced relaxation: 
Aortic rings were preincubated with either 100 nM or 50 nM CNP followed by ANP (500nM) addition 15 
minutes later. Controls were performed in the absence of CNP preincubations. Data shown represents 
means ± SD of 13 control experiments, 5 experiments with 100 nM and 7 experiments with 50 nM 
CNP, respectively. CNP induces significant (*P<0.01) increases in vasorelaxation. 
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Figure 13: ANP-induced relaxation of precontracted rat aorta after 50 nM CNP 
preincubation:  
Precontracted aortae were incubated with CNP (50nM) for 15 minutes prior to the addition of ANP 
(500nM), as indicated by arrows. While CNP itself did not induce any tension reduction, 
vasorelaxations by ANP was intensified to a value of 86%. Data shown is a representative of 7 
experiments performed 
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3.2.7 ANP-induced relaxation after pretreatment with PKA-inhibitor and 
50 nM CNP 
The apparent booster effect by CNP on ANP-induced relaxation suggested a CNP-
mediated sensitization of GC-A.  In this case an intracellular signaling pathway is 
required to elicit GC-A sensitization in response to GC-B activation by CNP. Since 
protein kinase A (PKA) was found to be an essential component of these signaling 
pathways in αT3 cells, the next experiment served to examine whether PKA is also 
implicated in CNP-induced GC-A sensitization in smooth muscle cells of the aorta.  
For this purpose, aortic rings were pretreated with Rp-8-Br-cAMPS, a cell permeable 
inhibitor of PKA, prior to CNP exposure with50 nM CNP and ANP was added 15 
minutes later to elicit vasorelaxation. 
These studies (Fig. 14 shows a typical trace) revealed that inhibition of PKA 
completely abolished the CNP effect demonstrated in prior experiments. Quantitative 
evaluation of such assays (Fig. 15) confirmed that the CNP-induced increase in ANP-
evoked relaxation was completely blocked when aortae were pretreated with PKA 
inhibitor. Thus, these findings provided evidence that PKA is implicated as mediator 
of CNP-induced sensitization of GC-A not only in αT3 cells but also in vascular 
smooth muscle cells. 
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Figure 14: ANP induced vasorelaxation after preincubation with PKA inhibitor and CNP 
After contraction was induced by NE and vasotone reached steady state levels, Rp-8-Br-cAMPS 
(30µM), a PKA inhibitor, was pipetted into the organ chamber, followed by addition of CNP ( 50 nM)  
10 min later. After additional 15 min, relaxation was induced by 500 nM ANP. Times of agent addition 
are indicated by arrows. Results shown are representative of 6 experiments performed. 
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3.3 Measurement of cGMP production in rat aorta 
To further investigate function of GC-A and GC-B, experiments were carried out to 
assess their enzymatic activities by measuring ligand-dependent cGMP production. 
These experiments were performed with freshly dissected thoracic aortae after 
removal of adherent fat and connective tissue. Individual aortae were cut 
longitudinally into two halves (approximately 18mg each) and these were further 
processed in parallel to examine treatment effects. To facilitate physiologically 
relevant reactions, pre-treatments were generally performed in the absence of 
phosphodiesterase inhibition. To assess receptor activities after pretreatments, 
Figure 15: PKA inhibition abrogates CNP effect: 
NE-contracted aortic rings were pretreated in the absence (control) or presence of CNP (50nM) alone or 
CNP+PKA inhibitor (Rp-8-Br-cAMPS) (30µM). Data shown represents means ± SD, number of  
experiments are indicated in parentheses.  
Results 
___________________________________________________________________ 
60 
samples were treated with high ligand (ANP or CNP) concentrations (0.5 µM) in the 
presence of IBMX to inhibit cGMP degradation.  
 
3.3.1 ANP is more potent than CNP to stimulate cGMP production in rat 
aorta 
 
Initial studies served to characterize basal (unstimulated) and natriuretic peptide-
induced cGMP production in the rat aorta. Equivalent aorta samples were incubated 
in either the absence or presence of natriuretic peptides (ANP, CNP, 0.5µM each) for 
30 minutes at 37°C under conditions (co-incubation with the phosphodiesterase 
inhibitor IBMX to prevent cGMP degradation). Reactions were stopped by chilling. 
After immediate centrifugation (3min, 15.000g), supernatants were removed and 
used for determination of cGMP by ELISA. 
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Figure 16: ANP- (A) and CNP- (B) stimulated cGMP production in rat aorta: 
Aorta samples were incubated in the absence (basal) or presence (0.5µM) of either ANP (A) or CNP 
(B). Solutions contained IBMX (0.2mM) to inhibit PDE activity. After 30 min at 37°C, reactions were 
terminated by chilling. Samples were centrifugated, and levels of cGMP in the supernatant fractions 
were determined by ELISA. Data shown represents means ± SD of 5 experiments with duplicate 
determinations of cGMP each. Both ANP and CNP induced significant (*P<0.005) increases in cGMP. 
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As calculated for simple thoracic aortae, these studies (Fig.16) revealed basal values 
of about 0.8pmol cGMP and significant increases elicited by ANP (Fig. 16A) and CNP 
(Fig. 16B). Interestingly, ANP was much more effective than CNP to accumulate 
cGMP, resulting in 18-fold (ANP) versus 2-fold (CNP) increases as compared to 
basal (Fig. 17). 
These findings provided evidence for a markedly higher abundance of enzymatically 
active ANP (GC-A) than CNP (GC-B) receptors in aortic tissue. Remarkably, this 
situation is different from that in αT3 cells, where CNP is more effective than ANP in 
promoting cGMP production (Introduction). 
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3.3.2 Pre-treatment with CNP enhances ANP-induced cGMP production 
Relaxation of smooth muscle by ANP is mediated via GC-A produced cGMP (Potter, 
Abbey-Hosch et al. 2006). Since pretreatments with CNP enhanced the vasorelaxing 
activity of ANP in isometric tension studies, the next experiments served to examine 
whether CNP also enhances the cGMP-generating potential of ANP. To address this 
Figure 18: Fold increase of cGMP induced by ANP and CNP, respectively 
 
Figure demonstrates the potencies of ANP and CNP to accumulate cGMP in aortic tissue. Values 
represent the mean ± SD of ANP/CNP elicited fold increase of cGMP compared to those cGMP 
levels measured in the absence of natriuretic peptides. Data is caculated from experiments shown 
in Fig. 16. 
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issue, aorta samples were incubated for 15 minutes in either the absence or 
presence (100nM) of CNP. After medium removal and washing, both samples were 
exposed to ANP (500nM) plus IBMX, and cGMP production determined. Results 
show (Fig. 19), that pre-exposure to CNP increases ANP-triggered cGMP 
accumulation significantly. This outcome is completely consistent with the results of 
the organ bath experiments, indicating a direct correlation between vasorelaxation 
and accumulation of cGMP due to activation of GC-A.  
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Figure 19: Pre-treatment with CNP enhances ANP-induced cGMP production 
Aorta samples were pre-incubated for 15 min at 37°C in either the absence (-CNP) or the presence 
(100nM) of CNP (+CNP). After medium removal and washing, samples were incubated for 20 min in 
the presence of ANP (500nM) and IBMX (0.2 nM). Amounts of cGMP produced were measured by 
ELISA. As figure indicates, pre-treatment with CNP enhances ANP-induced cGMP production 
significantly (*p<0.001). Amounts of cGMP measured in the control (-CNP) are indicated as 100%. 
Data represents means ± SD of 7 assays with duplicate determinations of cGMP each. 
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3.3.3 Pre-treatment with different CNP concentrations 
Since organ bath studies revealed a reciprocal dose-dependent effect of CNP 
(50nM>100nM) on ANP-induced vasorelaxation, analogous experiments for cGMP 
measurements were carried out. Samples were pre-exposed to CNP prior to ANP-
dependent stimulation in the same manner as described above, using two different 
CNP concentrations (50nM and 100nM). These studies (Fig. 19) showed that CNP is 
more effective at lower doses, suggesting that higher peptide concentrations 
attenuate this effect. Thus, the findings corroborated a CNP-induced sensitization of 
GC-A and supported the view that pre-incubations with CNP at concentrations 
(=100nM) allowing interaction of this peptide with GC-A diminish maximum effects by 
inducing GC-A desensitization. 
 
            
 
 
 
 
 
 
Figure 20: Comparison between different CNP concentrations used as pre-treatment 
Samples were incubated with either 50 nM or 100 nM CNP for 15 minutes. After medium removal and 
washing, samples were incubated with 500 nM ANP and IBMX to facilitate ANP-dependent cGMP 
production. Reactions were terminated by chilling, after which supernatant fractions were analyzed  for 
cGMP by ELISA. Controls were incubated in the absence of CNP. The amounts of cGMP measured in 
control samples were indicated as 100%. Data represents means ± SD of at least 3 independent 
experiments. 50nm CNP generates significantly (*p<0.05)  higher effects than 100nM with duplicate 
determinations of cGMP each. 
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Moreover, these findings provided further and convincing evidence for a direct 
correlation between the enzymatic activity of GC-A in synthesizing cGMP and the 
cellular response (relaxation) in vascular smooth muscle cells. 
 
3.3.4 GC-A sensitization is mediated through PKA 
Based on the results from the isometric tension studies with regard to signaling role 
of PKA, analogous experiments were performed to see whether CNP-induced 
enhancement of cGMP production is also affected by the PKA inhibitor, Rp-8-Br-
cAMPS. Test samples were pre-incubated with Rp-8-Br-cAMPS for 10 minutes to 
allow for cell entry and inhibition of PKA. Then CNP was added and incubated with 
aorta samples for 15 minutes. After medium removal and washing, samples were 
incubated with ANP. After 30 minutes, supernatant fractions were removed and 
analyzed via ELISA for cGMP accumulation. Controls were carried out in the same 
manner except for omission of the PKA inhibitor during the first step.  
The results (Fig. 21) demonstrated that, similar to the tension studies, Rp-8-Br-
cAMPS significantly reduces the CNP effect on GC-A activity. Thus, these results 
supported an involvement of PKA in the signaling pathway leading to sensitization of 
GC-A. 
If this is true, an activation of PKA should mimic the effect of CNP. To test this 
hypothesis, samples were incubated with the cell permeable cAMP-analog, 8-bromo-
cAMP, for 15 minutes. Again controls were performed 100 nM CNP. After washing 
and subsequent treatment with ANP, cGMP levels in the 8-bromo-cAMP- and CNP-
pretreated samples were in the same range. (Fig. 21) Thus, inhibition of PKA 
abolishes and activation of PKA mimics the CNP effect on GC-A activity, providing 
clear cut evidence that PKA serves as an essential mediator of this reaction. 
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3.3.5 CNP-induced GC-A sensitization is mediated through activation of 
GC-B 
As the previous results established the role of PKA as a mediator of CNP-induced 
GC-A sensitization, the next studies served to confirm that this signaling pathway is 
in fact initiated by CNP. 
To address this issue, the receptor antagonist (Sano, Imura et al. 1992) HS-142 was 
used to block receptor-ligand binding. Aorta samples were pre-incubated with CNP 
alone or CNP plus HA-142 for 15 minutes, then medium was removed and samples 
Figure 21: PKA inhibiton blocks and PKA activation mimics CNP-dependent 
sensitization of GC-A 
Aorta samples were pre-incubated for 20 min in either presence of CNP (100nM), CNP plus 
Rp-8-CPT-cAMPS (20µM) or with 8-bromo-cAMP (1mM). After medium removal and washing, 
all samples were treated with ANP (500nM) and IBMX (0.2 mM) for 30 min to assess GC-A 
activity. Amounts of cGMP were measured in supernatant fractions after centrifugation. 
Subsequently medium was removed and and incubation with ANP of 30 minutes followed. 
Values are means ± SD of 5 assays with duplicate determinations of cGMP each. CGMP levels  
assayed in controls (CNP) are indicated as 100% (*P<0.01) vs. CNP control. 
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were washed. After addition of ANP and incubation for 30 min supernatant fractions 
were obtained for determination of cGMP. Results (Fig. 22) demonstrated that co-
incubation with HS-142 the CNP effect was completely absent.  
Since HS-142 blocks also GC-A, it was important to control whether the ANP-induced 
cGMP production could have been affected under the experiments conditions. This 
would be conceivable if HS-142 is resistant to the washing procedure and remains 
receptor-attached. To check this item samples were treated either with or without HS-
142 as above prior to washing and incubation with ANP. These experiments (Fig. 22) 
did not reveal any effects on ANP-elicited cGMP production, indicating the observed 
inhibitory activity of HS-142 during CNP-pretreatments was due to blocking CNP/GC-
B interaction. 
Therefore, these findings showed that the signaling pathway leading to sensitization 
of GC-A requires CNP-dependent activation of GC-B. 
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Figure 22: CNP-induced sensitization is mediated through activation of GC-B 
Aorta samples were pre-incubated with either CNP, CNP plus HS-142, HS-142 or in the absence of 
these agents (H20) for 15 minutes and then washed and subsequently incubated with ANP for 30 min. 
Amounts of cGMP were measured via ELISA. Values are means ± SD of 4 assays with duplicate 
determinations of cGMP each. Data are expressed as percent in relation to the values obtained after 
CNP treatment (=100). 
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3.3.6 Homologous desensitization of GC-A 
After identifying molecular signaling events responsible for sensitization of GC-B, the 
goal of further studies was to examine homologous (i.g. agonist-induced) 
desensitization of GC-A in rat aorta. Desensitization of signaling pathways following 
their activation by ligand binding to plasma membrane receptors represents an 
important and widely used mechanism to control signal intensity. In the case of GC-
A, ANP exposure induces decreases in hormone sensitivity (Muller, Cortes-Dericks et 
al. 2006; Potter, Abbey-Hosch et al. 2006). Thus, aorta samples were pretreated for 
15 minutes in either the absence or presence of ANP. After medium was removed, 
both samples were re-incubated with ANP for 30 minutes, followed by measurements 
of cGMP. Results (Fig. 23) show, that pre-exposure to ANP leads to a significantly 
decreased receptor activity during a following stimulation. These findings 
demonstrated convincingly that ANP and CNP induce converse changes of GC-A 
activity in aortic tissue (Fig. 23). Moreover, the detection of ligand-induced 
desensitization of GC-A confirms the concept that sensitization of GC-A by CNP 
signaling is diminished at those CNP concentrations (≥100nM) that permit binding to 
and cross-reaction of GC-A. 
 
 
 
 
 
Results 
___________________________________________________________________ 
68 
                          
control + CNP + ANP
0
50
100
150
200
Preincubation
A
N
P
-e
lic
it
e
d
 c
G
M
P
(%
 o
f 
c
o
n
tr
o
l)
 
 
Figure 23: Homologous desensitization of GC-A in rat aorta 
Samples were pre-incubated for 15 min in either the absence (control) or presence (100nM) of CNP or 
ANP. After medium removal and washing samples were treated for 20 min with ANP (500nM) in the 
presence of IBMX. Resulting cGMP levels were determined by ELISA. Amounts of cGMP in control 
samples were set as 100%. Both CNP and ANP elicited significant effects (*P<0.01) 
Values are means ± SD of 7 experiments with duplicate determinations of cGMP each. 
 
 
3.3.7 Homologous desensitization of GC-A is mediated through PKG 
Considering that binding of ANP to GC-A initially stimulates the generation of cGMP, 
it is most likely that cGMP acts as a messenger molecule in the signaling pathway 
leading to desensitization of GC-A. Sine protein kinase G (PKG) is one of the most 
important cellular target proteins of cGMP, experiments were designed to examine 
whether PKG inhibition affects homologous desensitization of GC-A. Pre-incubations 
of aorta samples with ANP were carried out in either the absence or presence of the 
cell-permeable PKG inhibitor Rp-8-br-PET cGMPS. After medium exchange and 
identical treatments with ANP, cGMP levels in the samples pre-treated with ANP plus 
PKG inhibitor were significantly higher than in the samples exposed to ANP only (Fig. 
24). Thus, these findings provided evidence that inhibition of PKG blocks 
homologous desensitization of GC-A, indicating that PKG activity is implicated in this 
* 
* 
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reaction. In contrast, analogous experiments performed with PKA-inhibitor (Rp-8-
CPT-cAMPS) instead of PKG inhibitors did not show significant effects (Fig. 24). 
From this data, it can be concluded that PKG but not PKA is implicated in the 
signaling pathway underlying homologous desensitization of GC-A. 
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Figure 24: Effects of PKG or PKA inhibition on ANP-induced homologues 
desensitization of GC-A 
Aorta samples were pre-incubated for 20 min with either ANP (100nM), ANP plus PKG inhibitor, Rp-8-
br-PET-cGMPS (4µM), ANP plus PKA inhibitor, RP-8-CPT-cAMPS ((20µM). After medium removal 
and washing samples were treated with ANP (500nM) for 20 min. Following centrifugations, 
supernatant fractions were used for cGMP determination. Data represents means ± SD of 4 
experiments, using duplicate determinations of cGMP each. Amounts of cGMP are indicated in relation 
to those found in ANP-pretreated assays (=100%). *P<0.01 vs. ANP. 
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3.3.8 CNP-elicited sensitization of GC-A under conditions of PKG 
inhibition 
The striking phenomenon that 100 nM CNP was less efficient in evoking GC-A 
sensitization than 50 nM was explained by opposing effects elicited at the higher 
peptide concentration: sensitization of GC-A by binding to GC-B and desensitization 
of GC-A by binding of certain amounts of CNP to GC-A. The above findings that PKG 
specifically mediates the desensitization of GC-A upon ligand binding raised the 
possibility to prove this functional interaction experimentally. Inhibition of PKG during 
pre-treatment with 100 nM CNP should selectively repress the desensitization 
reaction, leading to enhanced hormone-dependent GC-A activity. In fact, 
pretreatments of aorta with 100 nM CNP in the presence of the PKG inhibitor Rp-8-
br-PET-cGMPS elicited significantly higher (by about 25%) degrees of GC-A 
sensitization than control assays without the inhibitor (Fig. 25). For comparison, the 
effects of PKA inhibition and 8-br-cAMP are co-demonstrated. 
In conclusion, these findings revealed that GC-A activity in aortic tissue is under 
concomitant control by both CNP/GC-B and ANP/GC-A signaling. The former leads 
to PKA-mediated receptor sensitization, the latter to receptor desensitization in a 
PKG-dependent manner. 
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Figure 25: Effects of PKA or PKG inhibition on CNP-induced sensitization of GC-A 
Aorta samples were pre-exposed to either CNP (100nM), CNP+Rp-8-CPT-cAMPS (20µM), 8-br-cAMP 
(1mM) or CNP+Rp-8-br-PET-cGMPS (4µM) for 15 min. Pretreatments were followed by medium 
exchange and addition of ANP (500nM), cGMP amounts, produced after 30 min were determined by 
ELISA. Values are means ± SD from 5 experiments with duplicate determination of cGMP each, 
indicated in % in relation to the CNP control (=100). Rp-b-br-PET-cGMPS significantly enhanced 
(*P<0.05) and Rp-8-CPT-cAMPS reduced (*P<0.005) the CNP effect. 
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4 Discussion 
4.1 Physiological roles of GC-A and GC-B in 
mammals 
The importance of GC-A in the regulation of blood pressure is well established 
(Tremblay, Desjardins et al. 2002). Targeted deletion of either the receptor (GC-A) or 
its ligand (ANP) resulted in chronic arterial hypertension and sudden death (Lopez, 
Wong et al. 1995; John, Veress et al. 1996; Oliver, Fox et al. 1997; Kuhn 2003). In 
numbers, the lack of ANP or GC-A in mice, enhanced blood pressure by 20 to 40 mm 
Hg, whereas blood pressure measured in animals with transgenically induced higher 
expression of ANP was 20 to 30 mm Hg lower than normal (Steinhelper, Cochrane et 
al. 1990; Potter, Abbey-Hosch et al. 2006). Though the regulatory functions of the 
ANP/GC-A system range from effects on intravascular volume to natriuresis and 
diuresis, the vasorelaxing potency is a key weapon to mediate hypotension 
(Winquist, Faison et al. 1984; Winquist, Faison et al. 1984; Potter, Abbey-Hosch et al. 
2006). Hitherto, the impact of natriuretic peptides on blood pressure has been widely 
attributed to vasodilatation of peripheral resistance vessels. In contrast, the function 
of conduit vessels such as the aorta in regulation blood flow has been mainly 
regarded as a passive mechanism based on the elastic characteristics of its 
connective tissue compositure.  
 
Further studies observed increases in intracellular cGMP upon ANP-induced 
vasorelaxation (Waldman and Murad 1987). The experiments of my thesis confirmed 
the crucial role of ANP as a potent vasodilator. Results show that ANP is capable to 
relax pre-contracted aortic rings in nanomolar concentrations. The vessel relaxation 
was pronounced and concomitant cGMP measurements revealed 20-fold increases 
in response to GC-A activation.  
 
The role of CNP in vasculature is controversial. Other functions, more established, of 
the CNP/GC-B system include inhibition of smooth muscle proliferation, oxidized low-
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density lipoprotein-induced migration of cultured human coronary artery smooth 
muscle cells, regulation of neointimal formation and suppression of intimal growth 
caused by artery injuries (Furuya, Aisaka et al. 1993; Shinomiya, Tashiro et al. 1994; 
Kohno, Yokokawa et al. 1997; Takeuchi, Ohmori et al. 2003; Schachner, Zou et al. 
2004). Importantly, CNP dependent GC-B signaling plays a pivotal role in enchondral 
ossification, and disruption of the murine CNP gene results in severe dwarfism and 
early death (Chusho, Tamura et al. 2001). Consistently, deletion of the CNP receptor 
GC-B results in dwarfism (Tamura, Doolittle et al. 2004; Tsuji and Kunieda 2005).  In 
humans, single mutations within GC-B alleles result in statistically shorter patients 
compared to average persons from respective populations (Bartels, Bukulmez et al. 
2004). Moreover, recent findings indicate roles of the CNP/GC-B system in 
neurogenesis. Perinatal abundance of GC-B in neurons suggests functions for GC-B 
in proliferation and maturation of neurons (Muller, Hida et al. 2009). Interestingly, 
some studies identified CNP as the long sought endothelium-derived hyperpolarizing 
factor (EDHF) (Hobbs, Foster et al. 2004; Scotland, Ahluwalia et al. 2005). However, 
this activity of CNP was postulated to depend on interaction of the peptide with the 
clearance receptor (NPR-C) rather than GC-B.  
CNP-deficient mice displayed normotensive blood pressure, suggesting that CNP is 
not important for regulation of blood pressure. 
However, vasorelaxing effects were attributed to CNP based on isometric tension 
studies with precontracted rat aortae (Drewett, Fendly et al. 1995).   
This apparent discrepancy could be explained by the possibility that the observed 
CNP-induced vasorelaxation was elicited by (unphysiological) interaction of CNP with 
the ANP receptor, GC-A. In fact, there is evidence that CNP can cross-react with GC-
A at peptide concentrations ≥ 100 nM (Muller, Middendorff et al. 2002). Experiments 
of my thesis, where cumulative addition of CNP to precontracted aortic rings 
generated significant vasorelaxation only at these high peptide concentrations 
strongly support this view. Therefore, the relevance of CNP signaling in the aorta, 
linked to GC-B-produced cGMP accumulations, probably applies to other cellular 
functions. In addition to the well established role of NPR-C as a NP clearance 
receptor (Matsukawa, Grzesik et al. 1999; Potter 2011), certain reports suggested 
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also NPR-C-associated vasorelaxing effects (Chauhan, Nilsson et al. 2003; Hobbs, 
Foster et al. 2004). Two lines of evidence, provided in my thesis, doubt a functional 
implication of NPR-C in vasodilation. First, NPR-C was localized by affinity labelling 
experiments predominantly to the vessel-surrounding connective tissue rather than to 
the media or endothelium. Second, treatments of precontracted aortic rings with the 
NPR-C-selective agonist cANF failed to generate any changes in vascular tone. 
Thus, these findings suggest that GC-A (alone) is the principal mediator of NP-
induced vasorelaxation in the aorta. 
 
 
4.2 Mechanisms of receptor regulation 
Desensitization of receptors following their activation by ligand binding represents an 
important and ubiquitary mechanism to control signal intensity and cellular 
responses.  
A variety of studies performed with different cell lines showed that prolonged 
exposure to ANP induces desensitization of GC-A (Koller, Lowe et al. 1991; Joubert, 
Labrecque et al. 2001; Potter and Hunter 2001; Kuhn 2003; Potter, Abbey-Hosch et 
al. 2006). Additionally, homologous desensitization of GC-A has been observed and 
characterized in cultured smooth muscle cells (Cahill, Redmond et al. 1990; 
Yasunari, Kohno et al. 1992).  
It has been well established, that ligand-dependent guanylyl cyclase activity 
correlates with the degree of receptor phosphorylation and that dephosphorylation 
represents the molecular mechanism responsible for desensitization (Potter and 
Garbers 1992; Bryan and Potter 2002; Kuhn 2003; Pandey 2005; Potthast and Potter 
2005; Potter, Abbey-Hosch et al. 2006).  
Two recent studies, using mass spectrometry for identification of phosphorylated 
residues, revealed six phosphorylation sites in both rat and human GC-B (Yoder, 
Stone et al. 2010) and seven sites in GC-A (Schroter, Zahedi et al. 2010; Yoder, 
Stone et al. 2010). Indicating a more complex regulation than initially thought, the 
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phosphorylation at one (serine-487) of the sites in GC-A was increased rather than 
decreased during ANP-induced desensitization (Schroter, Zahedi et al. 2010) .  
 
Homologous desensitization of GC-A is a rapid process, leading to significant 
decreases in ligand-dependent receptor guanylyl cyclase activity within few minutes. 
Previous studies performed with cell lines revealed reductions of GC-A activity by 26 
% after 10 min (Muller, Cortes-Dericks et al. 2006) and by up to 50 % after 30 min 
(Potter and Hunter 1999; Muller, Cortes-Dericks et al. 2006). Consistent with and 
supporting these findings, the data obtained in this thesis with intact aorta showed 
decreases in GC-A activity by 40 % after 15 min ANP pre-exposure. 
 
The cGMP-generating sGC also undergoes fast (“acute”) desensitization following 
agonist binding (Bellamy, Wood et al. 2000; Bellamy and Garthwaite 2001; Roy and 
Garthwaite 2006). Considering that cyclic nucleotide-mediated cellular effects are 
rapidly elicited (Honda, Adams et al. 2001) using compartmentalized pathways 
(Piggott, Hassell et al. 2006), acute desensitization may represent a general and 
essential cellular strategy to protect the cells from second messenger overload and 
the activation of undesired pathways. 
 
Additional cellular responses can emerge under conditions of chronically elevated 
hormone levels. As known from other signaling systems, these responses frequently 
include decreases in cell surface receptor densities. In the case of the GC activity-
containing NP receptors (and discriminating these receptors from NPR-C), 
investigations performed by most (Kato, Lanier-Smith et al. 1991; Koh, Nussenzveig 
et al. 1992; Vieira, Gao et al. 2001; Fan, Bryan et al. 2005) albeit not all (Pandey, 
Nguyen et al. 2002) groups argue against the existence of pathways capable of 
(rapidly) reducing receptor membrane concentrations by internalization/endocytosis. 
Such reactions may take place, however, after prolonged (>8 h) ligand exposure 
(Flora and Potter 2010). Indicating the possibility of additional long term effects, there 
is substantial evidence for agonist-induced downregulation of GC-A (Cao, Chen et al. 
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1998; Singh, Kuc et al. 2006) and GC-B (Rahmutula and Gardner 2005) at the gene 
expression level.  
 
Though much attention has been paid to the natriuretic peptide receptor 
phosphorylation itself, the kinase(s) and phosphatase(s) involved in this process still 
remain to be identified. Effects induced by the serine/threonine protein phosphatase 
(PP) inhibitors okaidic acid (Potter and Garbers 1992) and microcystin (Bryan and 
Potter 2002) suggested an implication of PP1 and/or PP2A in ANP-induced 
desensitization of GC-A. Further reports documented that heterologous GC-A 
desensitization in membranes of transfected mouse kidney 293 and NIH3T3 
fibroblast cells is mediated through a magnesium-dependent phosphatase, 
supposedly a member of the PP2C family (Abbey and Potter 2002; Bryan and Potter 
2002).  
 
It seems most likely, that cGMP, the second messenger generated by GC-A, is 
involved in signaling pathways that trigger desensitization of GC-A. In this end, 
cGMP-dependent protein kinase G (PKG) functions as a key intracellular mediator of 
cGMP signaling in various cell types (Kotera, Grimes et al. 2003). PKG is already well 
established as a downstream component of ANP/GC-A signaling. Effects attributed to 
PKG span from modulation of L-type calcium channels (Tohse, Nakaya et al. 1995) 
to cross-talks with heterologous receptors, such as G protein-coupled receptors 
(Pedram, Razandi et al. 2000; Yamamoto, Yan et al. 2001). Another study suggests 
that ANP-mediated cGMP accumulations regulate PKG-elicited phosphorylation of 
vasodilator-stimulated phosphoprotein (VASP) Ser-239 in endothelial cells, resulting 
in reorganization of the actin cytoskeleton and enhancement of angiogenesis (Chen, 
Levine et al. 2008). This data clearly supports pivotal roles for PKG in ANP signaling. 
Furthermore, there are reports on upstream targets of PKG, in a manner in which it 
may be able to regulate GC-A activity. Airhart et al. demonstrated such an upstream 
pathway in which ANP-activated GC-A recruits PKG to the membrane resulting in 
increased intrinsic cyclase activity in transfected and untransfected HEK 293 cells 
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(Airhart, Yang et al. 2003). This is also concordant with data demonstrating that PKG 
is capable of phosphorylating GC-A in vitro (Larose, Rondeau et al. 1992). 
 
As shown in this thesis, the specific PKG inhibitor Rp-8-br-PET-cGMPS blocks 
homologous desensitization of GC-A in rat aortic tissue. These findings provide 
evidence that cGMP accumulations in response to GC-A activation not only elicit 
PKG-mediated smooth muscle relaxation (Weber, Bernhard et al. 2007) but also 
PKG-mediated decreases in GC-A hormone responsiveness. Whether the latter 
reaction is based on PKG-induced phosphorylation of GC-A (at serine-487; see  
(Schroter, Zahedi et al. 2010) or on PKG-stimulated phosphorylation (and activation) 
of phosphatases that act on other GC-A residues remains to be elucidated. In any 
case, this data provides a further example for spatial and functional segregation of 
cGMP signaling pathways within cells (Muller, Greenland et al.; Neves, Tsokas et al. 
2008). Desensitization in direct response to elevated cGMP levels has also been 
observed in the case of sGC (Wykes, Bellamy et al. 2002). 
 
4.3 Co-expression of GC-A and GC-B in rat aorta 
Expression of GC-A mRNA was described in various tissues such as kidney, adrenal, 
ileum, lung, adipose and vasculature (Lowe, Chang et al. 1989; Schulz, Singh et al. 
1989; Nagase, Katafuchi et al. 1997). Further studies exposed high gene expression 
of GC-A in specific brain areas including the olfactory bulb, pineal gland, subfornical 
organ and other circumventricular organs (Langub, Watson et al. 1995; Herman, 
Dolgas et al. 1996). In contrast, data on GC-A protein levels are rare but identified 
expression in rodent lung, kidney and testis (Goy, Oliver et al. 2001; Muller, 
Mukhopadhyay et al. 2004). GC-A was also detected in vascular smooth muscle 
cells, but these findings were based on GC-A mRNA examinations and on ANP-
dependant cGMP accumulations without clear proof for receptor expression at the 
protein level (Suga, Nakao et al. 1992).  
Studies on GC-B expose high expression of mRNA in lung, adrenal, kidney, uterus 
and certain brain tissues (Schulz, Singh et al. 1989; Wilcox, Augustine et al. 1991; 
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Chrisman, Schulz et al. 1993; Nagase, Katafuchi et al. 1997). GC-B protein has been 
detected in fibroblasts (Chrisman and Garbers 1999; Abbey and Potter 2002; Abbey 
and Potter 2003). Thus, although reports on the tissue expression of both receptors 
are plenty, clear-cut evidence on their protein levels is scarce and hitherto restricted 
to few tissues.  Since blood pressure regulation is believed to be one of the hallmarks 
of natriuretic peptide signaling, it was of particular interest (and a major goal of this 
thesis) to characterize the expression of both receptors at the protein level in rat 
aorta.  
Based on previous findings in αT3-1 cells, where CNP/GC-B signaling was shown to 
induce sensitization of GC-A (Cortes-Dericks 2005), these studies should also focus 
on possible sites of cellular co-expression of the two receptors.   
Both immunoblotting and affinity crosslinking approaches consistently revealed high 
abundance of GC-A and GC-B protein in aortic tissue. Immunohistochemical 
analyses demonstrated that both receptors are localized to and co-expressed in 
vascular smooth muscle and endothelial cells. Thus, these two cell types are the 
principal targets for ANP and CNP in aortic tissue and provide a local molecular basis 
for cellular interactions between GC-A- and GC-B-induced signaling pathways. 
Moreover, as could be concluded from the immunohistochemical data, the vast 
majority of both receptors in the aorta are present in smooth muscle cells.  
Comparative affinity crosslinking experiments performed with aortic tissue that 
contained or did not contain the surrounding connective tissue elucidated additional 
important and novel information. These studies revealed that the natriuretic peptide 
clearance receptor, NPR-C, is predominantly expressed in the vessel-surrounding 
connective tissue and of lower abundance than GC-A and GC-B in the media and 
intima. This particular distribution of NPR-C suggests a most important role for the 
clearance receptor in controlling natriuretic peptide levels within the connective tissue 
around blood vessels and further questions an essential direct involvement in blood 
pressure regulation (Maack, Suzuki et al. 1987).  
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4.4 CNP/GC-B signaling sensitizes GC-A 
The above findings proved co-expression of GC-A and GC-B, two enzymes 
commonly generating the second messenger cGMP, in vascular smooth muscle (and 
endothelial) cells of the aorta. Therefore, this data allowed examine whether 
CNP/GC-B signaling in these crucial vascular cell types can also (like in αT3-1 cells) 
induce GC-A sensitization. 
 
As revealed in this thesis, pre-exposure of CNP to intact aortic tissue elicited an 
enhanced activity (hormone-responsiveness) of GC-A. This effect was demonstrated 
at the enzymatic (enhanced ANP-induced cGMP generation) and the functional 
(enhanced ANP-induced vasorelaxation) level. The latter findings clearly localized the 
crosstalk between CNP- and ANP-induced signaling, resulting in GC-A sensitization, 
to vascular smooth muscle cells. Since functional activities of ANP in endothelial cells 
were not addressed in this study, it remains unclear, whether CNP/GC-B signaling 
also affects endothelial GC-A. 
 
Strikingly, the potency of CNP to induce GC-A sensitization was greater at 50 nM 
than at 100 nM. Since CNP can cross-react with GC-A only at the higher (100 nM) 
concentration, this data indicates that CNP binding to GC-A can induce receptor 
desensitization and hence diminishes the activation evoked by CNP/GC-B signaling. 
Thus, these findings provide evidence for a dynamic regulation of GC-A in vascular 
tissue under the concomitant control of both desensitizing and sensitizing pathways.  
 
Different physiological roles of the two related receptors, GC-A and GC-B, are well 
established. However, functions exerted by both cognate receptors were examined 
hitherto almost exclusively with regard to one of them. Moreover, less attention has 
been paid to compartmentalization and possible distinct pathways of generated 
cGMP by both GC-A and GC-B in cells where both receptors are active.  
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Recent studies opened the gate for insight into receptor-specific activities in cells co-
expressing GC-A and GC-B. Accordingly, one study revealed that GC-B 
predominates in neurons of the developing brain whereas GC-A does so in the adult 
brain. Thus it has been postulated that CNP/GC-B signaling controls perinatal stages 
of brain development, whereas ANP/GC-A signaling is suggested to be responsible 
for different functions in the mature brain (Muller, Hida et al. 2009).  These findings 
strongly suggest distinct roles of GC-A and GC-B signaling within the same tissue. 
Moreover, experiments with αT3 cells (Cortes-Dericks 2005) specifically investigated 
receptor activities in a cell line co-expressing GC-A and GC-B and uncovered a novel 
mechanism of intracellular cross talk between these signaling systems.  
 
Enhanced ligand-dependent cGMP generation has been reported previously, when 
cellular effects of either isoproteonol, a beta adrenergic agonist (Kishimoto, 
Yoshimasa et al. 1994; Thibault, Lacasse et al. 1996), or NaCl-treatments (Katafuchi, 
Mizuno et al. 1992) have been investigated. Also, down-regulation of NPR-C levels 
was found to result in increased GC-A activity (Kishimoto, Yoshimasa et al. 1994). 
The present findings elucidate for the first time in a functional context (and performed 
with intact tissue) a mechanism by which the hormone-responsiveness of GC-A is 
increased.  
 
In conclusion, these findings are of major significance for the following reasons: 
First, they strongly suggest a compartmentalized signaling of cGMP in cells co-
expressing GC-A and GC-B. It is shown clearly that cGMP generated by GC-A elicits 
downstream events resulting in vasorelaxation and at the same time it is involved in 
upstream events leading to enzymatic downregulation of GC-A. Interestingly though, 
CNP/GC-B dependent cGMP accumulation does not lead to vasorelaxation at 
physiological CNP levels but induces enhanced activity of GC-A. This provides strong 
evidence that both receptors cross talk with each other through an intracellular 
pathway using the same second messenger in a compartmentalized manner. 
Secondly, this work shows for the first time under in vivo-like conditions sensitization 
rather than desensitization of GC-A, that is triggered via GC-B activation. Hence, 
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these findings are consistent with a mechanism of two distinct pathways evoking 
opposite effects on the same receptor. These new insights provide a basis for a 
dynamic regulation of GC-A. Considering the fact that CNP exerts its function in a 
paracrine fashion (Potter, Abbey-Hosch et al. 2006), it can be deduced that GC-A 
activity is controlled by the above mechanism not only rapidly but also locally. Since 
various cell types have been reported to express both receptors, and the same effect 
of CNP-induced sensitization has been found in 2 completely different cell types 
(pituitary αT3-1 and vascular smooth muscle cells), it seems likely that a mechanism 
of broad significance has been uncovered. 
 
 
4.5 Sensitization of GC-A is mediated via PKA 
Remarkably, CNP-induced sensitization of GC-A was found to be completely 
inhibited by blocking cAMP-dependent protein kinase A (PKA), leading to the 
conclusion that this kinase is an essential component of the signaling pathway. 
Involvement of PKA in GC-A regulation has already been reported when inhibition of 
PKA blocked ANP-induced desensitization of GC-A in MA 10 cells (Muller, Cortes-
Dericks et al. 2006). However, these cells do not express PKG, indicating that this 
PKA effect is a particular and cell type-specific phenomenon. 
A possible candidate to deliver the message from the cGMP system to the cAMP 
system is phosphodiesterase 3 (PDE3). In addition to PKG and cyclic nucleotide 
gated (CNG) ion channels, phosphodiesterases constitute a further principal target 
for cGMP. There are at least 11 highly regulated and structurally related PDE gene 
families (PDE1-11). The proteins control levels of cyclic nucleotides by degrading 
them upon activation and thus play a pivotal role in regulating cyclic nucleotide 
signaling. Moreover they are of great significance in maintaining a compartmentalized 
environment within cells (Conti, Richter et al. 2003). While some of the family 
members of PDE are strictly confined to degrade either one of the two cyclic 
nucleotides (cAMP. cGMP), some of them play a double role, providing a basis for 
cross talks between them. PDE2, which degrades both cGMP and cAMP, has an 
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allosteric regulatory site with high affinity to cGMP. Binding of cGMP at this site 
lowers the apparent Km for cAMP and results in
 activation of the cAMP-hydrolyzing 
activity of the enzyme (Martinez, Beavo et al. 2002; Martinez, Wu et al. 2002; 
Mehats, Andersen et al. 2002). Accordingly, inhibition of aldosterone production due 
to ANP-dependent GC-A activation in adrenal cells of the zona glomerulosa is a 
result of cGMP-dependent PDE2 stimulation that evokes attenuated cAMP signaling 
(MacFarland, Zelus et al. 1991). The significance and potency of this pathway has 
been recently highlighted by showing that ANP exposure to these cells nearly 
completely blocks forskolin-induced aldosterone production and PKA activity 
(Nikolaev, Gambaryan et al. 2005). These findings provide convincing evidence for 
the existence of rapidly acting and compartmentalized signaling pathways in this cell 
type, by which ANP evokes effects via a PDE2-mediated cross-talk with cAMP 
signaling. 
 
A second cAMP-hydrolyzing PDE, considered to be regulated by cGMP in vivo, is 
PDE3 (Shakur, Holst et al. 2001). In this case, cGMP acts as a competitive inhibitor 
of cAMP hydrolysis. The catalytic site is characterized by a similar high affinity for 
cGMP and cAMP but the enzyme degrades cAMP much faster (up to 10-fold) than 
cGMP (Rybalkin, Yan et al. 2003) suggesting that PDE3 in vivo primarily functions as 
a cAMP-degrading enzyme. Several cGMP-mediated responses in cardiac cells, 
such as potentiation of Ca(2+) currents and a attenuation of the responsiveness to 
beta-adrenergic receptor agonists, have been shown to result from effects of cGMP 
on cAMP hydrolysis (Zaccolo and Movsesian 2007). Thus, local accumulations of 
cGMP are able to evoke increasing cAMP levels through competitive inhibition of 
PDE3. Evidence for the existence of corresponding signaling pathways has been 
reported. As demonstrated concordantly using isolated perfused rat kidneys (Kurtz, 
Gotz et al. 1998) or whole animals (Beierwaltes 2006), stimulation of renin secretion 
by nitric oxide is mediated via a cGMP-elicited inhibition of cAMP degradation, and 
PDE3 has been defined as the signaling component implicated in this cross-talk. 
Other cellular reactions, induced by nitric oxide and suggested to be (at least in part) 
mediated by cGMP-dependent breakdown of the cAMP-degrading activity of PDE3, 
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include inhibition of platelet aggregation (Maurice and Haslam 1990), stimulation of 
calcium currents in cardiac myocytes (Kirstein, Rivet-Bastide et al. 1995), control of 
renal vascular resistance (Sandner, Kornfeld et al. 1999), and an impairment of 
TNFα-induced transcriptional activity of NFκB in vascular smooth muscle cells with 
proposed impact on inflammation and atherosclerosis-promoting processes (Aizawa, 
Wei et al. 2003).  
 
There is evidence that this mechanism is not confined to nitric oxide induced cGMP, 
generated by sGC, but also active in pathways originating from membrane guanylyl 
cyclases. CNP, acting via GC-B, significantly enhanced the heart rate response to 
vagal nerve stimulation due to a cGMP-PDE3-dependent pathway that increases 
cAMP-PKA-dependent phosphorylation of presynaptic N-type calcium channels 
(Herring, Zaman et al. 2001). Similarly, CNP-elicited decreases in atrial stroke 
volume were reported to be based on this mechanism (Wen, Cui et al. 2004). ANP-
induced cGMP accumulations as well as direct cGMP applications with subsequent 
inhibition of PDE3 and activation of PKA potentiate rectifier potassium channel 
currents in sinu-atrial node cells (Shimizu, Shintani et al. 2002). 
 
The requirement of PKA activity for sensitization of GC-A by CNP in αT3-1 and aorta 
smooth muscle cells suggest an involvement of PDE3 in this signaling pathway too. 
Inhibition of cAMP degradation by PDE3 in response to CNP/GC-B-produced cGMP 
accumulations represents a well conceivable mechanism by which local increases in 
cAMP (and subsequent activation of PKA) act as mediators of the reaction. This was 
confirmed by studies showing that treatment with 8-bromo-cAMP mimics the CNP-
induced sensitization of GC-A.  More importantly, recent experiments with PDE 3-
specific inhibitors (D. Müller, unpublished results) corroborated the role of this 
phosphodiesterase in the sensitization pathway.  
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Figure 26: Signaling pathways of GC-A and GC-B in vascular smooth muscle cells 
ANP-elicited stimulation of GC-A creates local accumulation of cGMP. PKG activation by cGMP 
evokes major cellular responses (relaxation) and desensitization of GC-A. On the other hand, co-
expressed GC-B is stimulated by CNP to produce cGMP. The latter inhibits PDE3 resulting in 
increased cAMP levels and activation of PKA, which in turn mediates sensitization of GC-A. 
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4.6 The aorta: a crucial independent target organ for 
natriuretic peptides? 
In many studies, including those of my thesis, the aorta was used as a representative 
for vasculature in general. Results obtained by such experiments generally served to 
apply them on peripheral vessel. Consequently, most studies about hormone-
dependent regulation of vascular tone paid attention to its impact on blood pressure 
in peripheral resistance vessels, and specific contributions by conduit vessels 
proximate to the heart such as the aorta were not addressed. In particular, the so 
called Windkessel effect created by the aorta has been disregarded in the context of 
hormonal regulation.  
 
It is thought that structural components dominate the biomechanical properties of the 
aorta. An elastic matrix forms lamella consisting of elastic fibers, collagens 
(predominantly type 3), proteoglycans, and glycosaminoglycans. When the left 
ventricle contracts to force blood into the aorta, the aorta expands. This stretching 
gives the potential energy that will help maintain blood pressure during diastole, as 
during this time the aorta contracts passively. This Windkessel effect of the great 
elastic arteries has important biomechanical implications. The elastic recoil helps 
conserve the energy from the pumping heart and smooth out the pulsatile nature 
created by the heart. Aortic pressure is highest at the aorta and becomes less 
pulsatile and lower pressure as blood vessels divide into arteries, arterioles, and 
capillaries such that flow is slow and smooth for gases and nutrient exchange (Belz 
1995) .  
Apart from peripheral resistance pressure maintained by small arterioles, the 
compliance of the aorta as the main conduit artery is a key component in regulation 
of arterial blood pressure and blood flow velocity, as 80% total compliance of the 
systemic arterial tree is located in the aorta (Saouti, Westerhof et al. 2010). 
Accordingly, reduced compliance, referred to as aortic stiffness, is associated with 
diseases such as cardio-vascular events (Vlachopoulos, Aznaouridis et al. 2010) and 
kidney insufficiency (Bahous, Blacher et al. 2009). Aortic stiffness is reported to be a 
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valuable biomarker to predict cardio-vascular events (Mitchell, Hwang et al. 2010). As 
the Windkessel function is regarded to be completely relying on the architectural 
composition of aortic tissue, the effects are considered to be mainly passively 
regulated. 
 
Interestingly, recent findings in our laboratories (D. Müller, unpublished results) 
showed that the expression density of GC-A and GC-B is much higher in aorta as 
compared to branching arteries or other established natriuretic peptide target tissues 
such as kidney and adrenal gland. Similar observations were made by analyses of 
human tissue samples. Moreover, as assessed by organ bath studies, ANP was 
found to be much more potent in eliciting vasodilation in aorta as compared to 
smaller peripheral arteries. 
These findings suggest a crucial active role for natriuretic peptides in regulation of the 
Windkessel effect of the aorta. Thus, the cross talk between GC-A and GC-B 
identified in this thesis may not only represent a novel mechanism of activity 
regulation of GC-A in cells co-expressing both receptors but may have particular 
physiological significance for enabling and maintaining a proper Windkessel function 
of the aorta.  
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Summary 
Regulation of hormone activity at the receptor level has crucial physiological impact. 
In the case of the cGMP-generating receptors (GC-A and GC-B) for the natriuretic 
peptides ANP, BNP and CNP, such a regulation occurs primarily by changes in the 
degree of receptor phosphorylation. Prolonged ligand exposure induces 
dephosphorylation resulting in reduced receptor hormone responsiveness, a process 
called homologous desensitization. 
Previous studies with pituitary cells that co-express GC-A and GC-B revealed an 
unexpected cross talk between ANP- and CNP-induced signaling pathways. 
Strikingly, CNP pre-exposure to the cells elicited increases in GC-A activity, and this 
reaction was apparently mediated by cAMP-dependent protein kinase (PKA). 
Goal of the present investigations was to examine whether such a cross talk may 
exist also in the vasculature, a most important natriuretic peptide target organ. Both 
GC-A and GC-B were found to be co-expressed at high levels in vascular smooth 
muscle cells of the rat aorta. Isometric tension studies revealed that CNP pre-
exposure enhances the vasorelaxing effect of ANP on vascular tone. Further 
experiments showed that this regulatory effect of CNP is initiated by activating GC-B 
and mediated through PKA. These findings were supported by assays carried out to 
show intracellular cGMP levels as indication for receptor enzymatic activity. 
Consistently, results demonstrated that pre-incubation with CNP evoked significantly 
higher amounts of cGMP production by GC-A. Moreover, vessels, pre-incubated with 
ANP, showed reduced GC-A activity, indicating that smooth muscle GC-A is also 
sensitive to desensitization mediated through protein kinase G (PKG). 
Thus, these findings corroborated the existence of a signaling pathway, by which 
CNP can increase the hormone-sensitivity of GC-A. This mechanism is apparently 
present and active in the vasculature to regulate the vasodilatory potency of ANP. 
Desensitization of GC-A, expected to take place under conditions of elevated ANP 
plasma levels, can be relieved by CNP/GC-B signaling. Since attenuation of the 
biological effects of ANP due to GC-A desensitization in various diseases associated 
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with enhanced ANP levels is a major clinical problem, the data indicates a 
considerable therapeutic potential of GC-B agonists. 
Zusammenfassung 
Die Regulierung der Hormonaktivität auf Rezeptorebene hat entscheidende 
physiologische Auswirkungen. Im Falle der cGMP-generierenden Rezeptoren (GC-A 
und GC-B) für die natriuretischen Peptide ANP, BNP und CNP vollzieht sich diese 
Regulation vorwiegend in der Änderung des Phosphorylierungsgrades des 
Rezeptors. Andauernde Bindung des Liganden führt zu einer Dephosphorylierung, 
die eine verminderte Empfindlichkeit des Rezeptors zum Liganden zur Folge hat. 
Diesen Prozess bezeichnet man als homologe Desensitisierung. 
Bisherige Studien mit Hypophysenzellen, die GC-A und GC-B coexprimieren, 
enthüllten einen unerwarteten „Cross-talk“ zwischen ANP- und CNP-induzierten 
Signalwegen. Auffallenderweise löst eine Präexposition der Zellen zu CNP eine 
erhöhte GC-A Aktivität aus. Diese Reaktion wird offensichtlich durch eine cAMP-
abhängige Proteinkinase (PKA) vermittelt. 
Das Ziel der vorliegenden Untersuchungen war herauszufinden, ob dieses 
Phänomen auch in Gefäßen vorzufinden sei, die schließlich ein wichtiges Zielorgan 
für natriuretische Peptide darstellen. Sowohl GC-A, als auch GC-B werden in glatten 
Muskelzellen der Rattenaorta reichlich coexprimiert. Organbadstudien zeigten, daß 
Präinkubation mit CNP die vasorelaxierende Wirkung von ANP versärkt. Weitere 
Experimente verdeutlichten, daß dieser Effekt durch die Aktivierung von GC-B durch 
CNP ausgelöst und von PKA vermittelt wird. Diese Ergebnisse werden durch 
Untersuchungen der intrazellulären cGMP-Konzentrationen als Indikator für die 
Rezeptoraktivität untermauert. Dementsprechend zeigte sich, daß die Präinkubation 
mit CNP zu einem signifikanten Anstieg der cGMP-Synthese durch GC-A führt. 
Darüberhinaus konnte demonstriert werden, daß Gefäße, die einer Präinkubation mit 
ANP ausgesetzt waren, eine verminderte GC-A-Aktivität zu verzeichnen hatten. Dies 
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weist eindeutig darauf hin, daß auch GC-A in glatter Muskulatur auf Desensitisierung 
reagiert, welche hingegen durch Proteinkinase G (PKG) vermittelt wird. 
Demnach bestätigen diese Ergebnisse einen vorhandenen Signalweg, mithilfe 
dessen sich die Hormonsensitivität von GC-A durch CNP steigern läßt. Dieser 
Mechanismus ist offensichtlich in der Vaskulatur präsent und aktiv und reguliert die 
vasorelaxierende Potenz von ANP. Die Desensitisierung von GC-A, im Falle von 
erhöhten Plasmakonzentrationen von ANP zu erwarten, kann vom CNP/GC-B 
System wieder aufgehoben werden. Da die Abschwächung biologischer 
Eigenschaften von ANP augrund einer Rezeptordesensitisierung in verschiedenen 
Erkrankungen mit einer erhöhten Konzentration von ANP einhergeht und somit ein 
relevantes klinisches Problem darstellt, weist diese Arbeit auf die besondere 
Bedeutung von möglichen CNP/GC-B-Agonisten und ihr therapeutisches Potenzial 
hin.
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Abbreviations 
 
ANP atrial natriuretic peptide 
ATP adenosine triphosphate 
BNP brain natriuretic peptide 
BSA bovine serum albumin 
cAMP cyclic adenosine 3’, 5’ monophosphate 
cANF atrial natriuretic factor 
cGMP cyclic guanosine 3’, 5’ monophosphate 
CHD cyclase homology domain 
CNG cyclic nucleotide gated 
CNP C-type natriuretic peptide 
ECL enhanced chemiluminescence 
ELISA enzyme linked immuno sorbent assay 
ERK extracellular-regulated protein kinase 
GC guanylyl cyclase 
GC-A guanylyl cyclase-A 
GC-B guanylyl cyclase-B 
GPCR G-protein coupled receptor 
HEK human embryonic kidney cell line 
HBSS Hank’s balanced salt solution 
HRP horseradish peroxidase 
IBMX 3-isobutyl-1-methylxanthine 
KHD kinase homology domain 
LPA lysophosphatidic acid 
NE norepinephrine 
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NIH3T3 mouse embryonic fibroblast cell line 
NP natriuretic peptide 
NPR-A natriuretic peptide receptor-A (alternative name of GC-A) 
NPR-B natriuretic peptide receptor-B (alternative name of GC-B) 
NPR-C natriuretic peptide receptor-C 
OA okadaic acid 
PAP peroxidase antiperoxidase   
PBS phosphate-buffered saline 
PDE phosphodiesterase 
PCR polymerase chain reaction 
pGC particulate guanylyl cyclase 
PKA cAMP-dependent protein kinase 
PKC phospholipid-dependent protein kinase 
PKG cGMP-dependent protein kinase 
PLC phospholipase C 
PP protein phophatases 
S1P sphingosine-1-phosphate 
SD standard deviation 
SDS sodium dodecyl sulphate 
SDS-PAGE sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
sGC soluble guanylyl cyclase 
SMC smooth muscle cell 
SNP sodium nitroprusside 
TBS Tris-buffered saline 
TBST Tris buffered saline-Tween 20 
TMB tetramethyl benzidin 
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Tris Tris(hydroxymethyl)aminoethane 
UV ultraviolet 
VASP vasodilator-stimulated phosphoprotein 
VSMC vascular smooth muscle cell 
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